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ABSTRACT 
Multimorbidity, Immune Checkpoint Inhibitor Use, and Healthcare Expenditures among Older 




With decades of unchanged cancer care with no added survival benefit, immune checkpoint 
inhibitors (ICI) changed the treatment landscape of late-stage melanoma in 2011.  A key factor in 
determining the use of ICIs is the presence of pre-existing chronic conditions, which can 
influence the outcome.  However, the prevalence of multimorbidity (defined as presence of two 
or more chronic conditions) among older patients with late-stage melanoma remains unknown.  
It also remains unknown if the presence of multimorbidity factors into the use of ICIs.  Hospital-
related factors associated with ICI use have been studied.  Yet, patient-level factors, such as age, 
sex, marital status, which may play a more crucial role in the use of ICIs, remain unknown.  
Furthermore, ICI use may exacerbate healthcare expenditures for an already expensive condition, 
i.e., late-stage cancer.  There are no studies exploring the effects of ICI on healthcare 
expenditures among the elderly.  Therefore, this study had three main objectives (1) to examine 
the prevalence and type of pre-existing multimorbidity and the associated risk factors, (2) to 
assess the association of multimorbidity and other risk factors on ICI use, and (3) to assess the 
impact of ICI and multimorbidity on healthcare expenditures among older patients with late-
stage melanoma.  Retrospective cohort studies were conducted using Surveillance, 
Epidemiology, and End Results cancer registry linked with fee-for-service Medicare claims for 
older (>66 years) patients with a 12-month pre-index and 12-month post-index period.  Index 
date was the date of incident stage III/stage IV melanoma diagnosis between 2011 and 2015.  
Logistic regression was used to examine the associations of multimorbidity or ICI use to various 
patient-level factors.  Generalized linear mixed models with gamma distribution and log-link was 
used to analyze adjusted relationships between ICI/multimorbidity and healthcare expenditures.  
In the first aim, an overwhelming majority (85%) of older adults with late stage melanoma had 
pre-existing multimorbidity.  The second aim concluded that only 6% of older adults with late-
stage melanoma received ICI.  Multimorbidity was not significantly associated with ICI use.  
Factors positively associated with ICI use were lower age, social support in the form of spouse, 
residence in the Northeastern regions, and had dual eligibility compared to their counterparts.  
This study concluded that patient-level factors may play a significant role in decisions towards 
treatment of late-stage melanoma with ICI, regardless of multimorbidity.  The third study 
reported that the average total, outpatient, home health, and inpatient healthcare expenditures in 
the pre-index period were significantly (p < 0.001) lower than the expenditures in the post-index 
period.  In addition, regardless of multimorbidity, the high expenditures in post-index period 
were influenced by the use of ICI.  Therefore, ICI use was significantly associated with 
healthcare expenditures.  In summary, multimorbidity is a growing concern for oncologists, 
especially among the elderly.  The high prevalence of multimorbidity among elderly in our study 
points to the fact that multimorbidity should be factored into cancer care.  Since multimorbidity 
is not included in cancer care guidelines, it does not play a role in receipt of ICI among older 
patients.  However, the use of ICI significantly increases healthcare expenditures.  To reduce 
costs, newer payment models that focus on value are being developed and tested.  Future studies 
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CHAPTER 1 
1. BACKGROUND AND SIGNIFICANCE 
1.1. Introduction 
Melanoma Prevalence and Incidence 
Melanoma is a type of skin cancer which arises from uncontrollable proliferation of 
melanocytes.1  Historically a rare cancer, its incidence has risen faster than any other cancer.1  
This rise in incidence has been primarily attributed to tanning beds, though other risk factors 
such as sun exposure and other environmental factors cannot be ruled out.1,2  The incidence rose 
from 1 in 1,500 in 1935 to 1 in 30 in 2015.3  In 2020, approximately 100,000 Americans will  be 
diagnosed with melanoma.4,5  This rise in incidence has made melanoma the fifth most common 
cancer in the United States (US).5  If caught early, prognosis of melanoma is favorable.3,6  
However, once melanoma has metastasized, treatment becomes difficult with a grim long-term 
prognosis; median overall survival rates range from 6 to 8 months.7,8  Further, the 1- and 2-year 
survival rates for patients with metastatic melanoma were 23% and 9% respectively.9 
Melanoma in the elderly 
Globally, the greatest burden of melanoma falls on residents of Australia, Europe, New 
Zealand, the elderly and male population.10  The incidence in the older population continues to 
rise in the US while the incidence in younger population appears to be leveling off.11  Nearly 
50% of all melanoma deaths in the US occur in white men older than 50 years.11  One of the 
reasons for higher death rates among the older population (>65 years) is immunosenescense, 
which means as we age, our immune system declines.11  Therefore, older patients have reduced 
capacity to fight infections and malignancy.  Another reason for the high mortality rate among 
the elderly is that several poor prognostic factors, including non-superficial spreading histology, 
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higher Clark invasion level, lower Breslow thickness, and presence of ulceration, were 
significantly observed in the elderly. 
In addition, as patients age, the factors of primary melanoma become more advanced and 
melanoma is more likely to develop poorer histological features.12  Therefore, older patients are 
more likely to be diagnosed with late-stage (Stage III/IV) melanoma.12  A study noted that older 
patients had higher primary tumor stage, higher Breslow thickness, ulceration, and poorer 
survival compared to younger (18-64 years) patients.12  Therefore, this dissertation will focus on 
older patients with late-stage melanoma. 
Treatment of late-stage melanoma 
Once melanoma has been diagnosed, there are multiple options for treatment.  Prior to 
2011, management of metastatic melanoma included single-agents (alkylating agents, 
microtubule disrupting agents, platinum analogs, and nitrosoureas), as well as combination 
chemotherapy along with surgery and radiation therapy.13,14  However, these therapies did not 
significantly improve survival and were often associated with high toxicity.14–16  This led to the 
advent of immune checkpoint inhibitors (ICI; including ipilimumab, nivolumab, and 
pembrolizumab) since 2011, which have significantly improved survival with less toxic side 
effects.17,18  A departure from chemotherapy, ICIs work by energizing the immune system of the 
body to fight off the cancer cells.17,18  Recent data of 5.3 years median follow-up for ipilimumab, 
an anti-CTLA-4 agent, yielded significantly better distant metastasis free survival compared to 
standard chemotherapy, with no additional toxicities reported since the initial report at 2.3 
years.19,20  Even superior overall survival, progression free survival, objective response rates, and 
better safety profile were observed with anti-PD-1/PD-L1 agents (nivolumab and 
pembrolizumab).20–22  This led many researchers to explore the efficacy of combination ICI. 
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Early data from ongoing randomized clinical trials (RCTs) have shown durable response with 
combination ipilimumab and nivolumab.23  Such promising results from RCTs led to the 
integration of ICI (monotherapy or combination) as the first-line treatment for metastatic 
melanoma.24,25 
Multimorbidity 
People often live with two or more chronic conditions.  Aging population and increase in 
life expectancy means that the number of people living with increasing number of chronic 
conditions will continue to rise.26  This “multimorbidity” or the coexistence of two or more 
chronic conditions in the same individual will have an impact on their safety in primary and 
specialty care.  The safety concerns arise due to multiple reasons, including26 
• polypharmacy, which may lead to poor medication adherence and adverse drug events, 
• complex management regimens, 
• more frequent and complex interactions with health care services leading to greater 
susceptibility to failures of care delivery and coordination, 
• the need for clear communication and patient-centered care due to complex patient 
needs, 
• demanding self-management regimens and competing priorities, and 
• more vulnerability to safety issues due to poor health, advanced age, cognitive 
impairment, limited health literacy, and comorbid depression or anxiety. 
Therefore, recent years has seen an increase in research on multimorbidity to alleviate the 
safety concerns for such individuals. 
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Multimorbidity in the elderly 
Studies have shown that prevalence of multimorbidity is on the rise worldwide.  A study 
conducted in one developed country reported that almost 25% of the entire population has 
multimorbidities.26  Recent literature has shown high levels of multimorbidity in low- and 
middle-income countries.26  Similar trend has also been observed in high-income countries.  For 
example, in Sweden, the prevalence of multimorbidity was 56.3% among adults aged 35 to 75 
years.27  In the United States (US), one in four adults were reported to have multimorbidity, with 
68% of the elderly individuals having two or more chronic conditions and 36% having four or 
more chronic conditions.28  Another study reported similar findings among Medicare 
beneficiaries: 62% aged 65 to 74 years, 75.7% aged 75 to 84 years, and 81.5% aged 85 years and 
above had multimorbidity.29  In addition, female Medicare beneficiaries had higher prevalence of 
multimorbidity compared to males.29 
Such high prevalence has serious consequences on health outcomes of the elderly.  
Studies have shown that multimorbidity is associated with an increased risk of death, disability, 
poor functional status, poor quality of life, adverse drug events, and other adverse outcomes.29–31  
Despite efforts to reduce multimorbidity among the elderly, the condition remains rampant.  
Therefore, studies as this are needed to provide information on the impact of multimorbidity on 
newly diagnosed conditions, such as cancer. 
Late-stage melanoma and multimorbidity 
Prevalence of multimorbidity among older patients with late-stage melanoma 
The prognosis, treatment, and health outcomes (including survival) of patients with late-
stage melanoma depends on a number of factors, including age, tumor characteristics, and 
presence or absence of comorbidities.29,32  The presence of comorbidities influence cancer 
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detection, treatment, and progression of cancer.  This in turn can affect the prognosis and long-
term survival of the patients.  Patients with comorbidities are at higher risk of complications and 
lower performance status, may have decreased quality of life, and may face more life-threating 
conditions.  Despite the importance of considering comorbidities in treatment and prognosis of 
melanoma, the prevalence of comorbidities has received little attention. 
There are few studies on the impact of comorbidities of melanoma stage of diagnosis, 
treatment, and health outcomes.  These studies reported that the prevalence of chronic conditions 
varies from 19% to 80% among adult patients with malignant melanoma.25,33–36  These studies 
did not focus on late-stage melanoma because of poor survival among those patients.  However, 
the advent of ICIs may result in an increase in late-stage melanoma survivors.  Therefore, 
identifying prevalent conditions in patients with late-stage melanoma will allow healthcare 
professionals to tailor their long-term care for each individual. 
Moreover, the studies do not usually include mental health conditions.  Literature also 
suggests that those with mental health conditions may have barriers to cancer care.37  However, 
most studies on patients with cancer have focused only on anxiety and depression; the presence 
of other mental health conditions, such as dementia, can also lead to less-aggressive cancer 
treatment because of compromised informed consent and adverse effects.38–41  Therefore, 
estimating the prevalence of any type of multimorbidity can be useful to the providers as well as 
patients. 
In addition, one of the conditions worrisome for oncologists is autoimmune disease.  This 
is because ICI therapy can induce autoimmune side effects affecting almost any organ system, 
specifically aberrant activation of immune cells against self-antigens, referred to as “immune-
related adverse events (irAE)”.42  Patients with pre-existing autoimmune diseases may be at a 
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greater risk for developing irAEs.43  Therefore, these patients were largely excluded from RCTs 
of ICI.  However, a recent study reported that the prevalence of autoimmune diseases has been 
increasing from 17.1% in 2004 to 28.3% in 2014.36  Although autoimmune diseases are more 
frequent in the older patients, occurrence of autoimmune disease multimorbidity remains 
unknown.  Therefore, a study which included a comprehensive list of mental health conditions 
and autoimmune diseases is necessary because studies often include only limited mental health 
conditions and no autoimmune diseases.  In addition, examining factors (i.e., risk profile) other 
than age that may be associated with multimorbidity can help in assessing disease burden, 
surveillance, treatment decisions, and survivorship plans of patients with late-stage melanoma, 
justifying rationale for Aim 1. 
Factors associated with ICI use among older patients with late-stage melanoma 
Since the approval of ICI in 2011, literature on the improved survival associated with 
ICIs have increased exponentially.  It stands to reason that the use of ICI in real-world setting 
may be commonplace.  However, that is not the case; adoption of ICIs has been slow.  We 
speculate few reasons for this slower diffusion of innovation.  First, with their strict inclusion 
and exclusion criteria, RCTs of ICIs did not provide robust evidence on the use and impact of 
ICI among the elderly.  Additionally, multimorbidity is prevalent among the older patients.  
Layering the management of melanoma onto the management of a patient with multimorbidity 
further compounds the complexity of care.  The interplay between treatment approaches used for 
melanoma care and those used for multimorbidity can be complicated.  In patients with pre-
existing multimorbidity, a new diagnosis of cancer adds a new dynamic, with the primary care 
physicians and other specialists shifting into supportive roles, to deliver non-cancer care in the 
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context of cancer treatment.44,45  With lack of evidence from RCTs, decision-making on 
choosing ICI treatment for care may become difficult. 
In addition, certain patient-level factors may be considered as a source of slower adoption 
of newer therapies.  Studies on other cancers have shown some subgroups may be less likely to 
receive treatment.  For example, age and racial disparities on treatment received was reported 
among older patients with late-stage pancreatic adenocarcinoma.46  Patients below the age of 80 
years and White non-Hispanics were more likely to receive treatment than those above 80 years 
of age and other race/ethnicity.46  Similarly, a study among older patients with bladder cancer 
reported better survival among married patients than unmarried ones, because of greater 
likelihood of receiving treatment.47  Financial aspects potentially affecting the care setting for 
late-stage melanoma patients may also be a potential reason.48  Insured patients are more likely 
to receive ICIs compared to uninsured or underinsured patients.49  With evident disparities in 
receipt of treatment, it is critical to know whether some subgroups lag in the diffusion of 
innovative therapies like ICIs, so that oncologists and patients alike can make informed 
decisions when considering ICIs as the treatment option, thus justifying rationale for Aim 2. 
Healthcare expenditure associated with ICI among older patients with multimorbidity and 
late-stage melanoma 
The economic burden associated with cancer is substantial.  There is robust evidence that 
cancer increases healthcare expenditures.  The costs differ by type and stage of cancer.  
Therefore, although the cost of malignant melanoma is the lowest compared to other cancers, 
metastasis of melanoma significantly increases healthcare expenditures. 50–52  In fact, 55% of the 
annual direct cost for treating melanoma arose from late-stage melanoma and one-third of the 
total cost was related to the end-of life melanoma treatment.53  The annual treatment costs ranged 
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from $44.9 million among Medicare patients with existing melanoma to $932.5 million among 
newly diagnosed cases across all groups.54  Among Medicare beneficiaries, the average per-
patient melanoma charges were $2,194 during the initial four months of treatment and increased 
to $3,933 during the terminal six months of treatment in 2010.55 
Such costs are bound to increase with time due to inflation.  However, recent years has 
seen a substantial increase in cancer-related healthcare costs.  The high healthcare expenditures 
for late-stage melanoma may be driven by many factors such as high cost of ICIs, the associated 
administration costs for these drugs, and supporting care (monitoring and testing).56  One of the 
concerns are the high costs of ICIs.  According to Dr. Leonard Saltz, the costs of newer therapies 
“approximately 4,000 times the cost of gold”.57  He calculated that the cost for a typical patient 
receiving the CheckMate067 combination (ipilimumab and nivolumab) would have been 
$295,566.57  With a 20% co-pay, the out-of-pocket cost to the patients would have totaled 
$60,000.  In addition, serum biomarker testing and enzyme level monitoring are common before 
and during treatment of late-stage melanoma.58  These functions also factor into the cost of 
melanoma care.  Therefore, this amounted to $174 billion for treating late-stage melanoma for 
one year only.57 
Further, the presence of multimorbidity may further exacerbate the costs.  Healthcare 
resource utilization is high among patients with multimorbidity, with frequent visits to specialists 
and higher hospitalization rates.  Therefore, there was a positive associated between 
multimorbidity and healthcare costs, with an average increase of $1,774 in total costs for each 
body system affected by chronic conditions.59  It is reasonable  that older adults with 
multimorbidity treated with ICIs will therefore incur the highest healthcare expenditures. 
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It should be kept in mind that almost no patients pay for their treatments.  Rather, the 
society collectively pay the price for the expensive therapies.  When an individual gets a 
treatment, others pay through insurance premiums and/or taxes that support Medicare, Medicaid, 
or other government programs.  Therefore, when medical costs increase, so do the insurance 
premiums.  These rising premiums may in turn harm the very people who need it the most, by 
reducing their access to care because  they may be unable to purchase coverage. Examining the 
healthcare expenditures and the reason behind the increase will allow various stakeholders- 
healthcare professionals, payers, organization- to identify and condemn practices with 
unreasonable costs, thus justifying the rationale for Aim 3. 
1.2. Innovation 
a) Comprehensive evaluation of chronic conditions among older patients with late-
stage melanoma: This is the first study to include a comprehensive list of physical and mental 
health conditions when evaluating the prevalence of multimorbidity.  In addition, the updated list 
includes the autoimmune diseases based on the current challenges with ICI use. 
b) Novel factors of ICI adoption:  Studies have evaluated the role of healthcare 
practices in adopting ICIs.  However, patient-level factors have not been evaluated.  As shared 
decision-making is common practice, patient-level factors that influence the adoption of newer 
therapies might provide oncologists with leads to make headway on improving uptake of ICIs. 
c) Fill a significant knowledge gap in literature:  Given that no studies have examined 
multimorbidity among older patients with late-stage melanoma, the proposed study will fill an 
important knowledge gap in the literature by identifying the prevalence of various chronic 
conditions in such patients. 
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1.3. Specific Aims 
Aim 1.1: Estimate the prevalence and type of multimorbidity prior to the diagnosis 
of late-stage melanoma 
Aim 1.2: Evaluate the association of patient-level factors to multimorbidity in older 
patients with late-stage melanoma 
Hypothesis 1.2: In the fully adjusted model which will include all the independent 
variables, age will be significantly associated with multimorbidity among older patients with 
late-stage melanoma. 
Aim 2: Examine the association of multimorbidity and other factors to ICI use that 
cover years from the initial introduction in 2011 to 2015 among older patients with late-
stage melanoma 
Hypothesis 2: In the fully adjusted model, year of diagnosis, age, marital status, dual 
eligibility, and region of residence will be significantly associated with ICI use among older 
patients with late-stage melanoma. 
Aim 3.1: Estimate the impact of ICI use on healthcare expenditures during pre- and 
post-late-stage melanoma diagnosis periods among older patients with late-stage melanoma 
Hypothesis 3.1: ICI use will be associated with high expenditures throughout the 
treatment period compared to those without ICI use. 
Aim 3.2: Estimate the impact of ICI-multimorbidity interaction on healthcare 
expenditures during pre- and post-late-stage melanoma diagnosis periods among older 
patients with late-stage melanoma 
11 
Hypothesis 3.2: Patients who used ICI and had multimorbidity will have higher 
expenditures throughout the treatment period compared to ICI non-users and those without 
multimorbidity. 
1.4. Approach 
Conceptual Frameworks Used to Guide the Selection of Variables 
A conceptual framework was created by adapting determinants of health outcomes and 
chronic disease model and Andersen’s healthcare utilization model.60,61  According to these 
models, outcomes 
such as presence of 
multimorbidity, 
receipt of novel 
therapies (ICI), and 
consequently 
healthcare 
expenditures are based 
on the presence or 
absence of multiple 
factors.  These factors included biological factors, social factors, community resources, socio-
economic status, and year of diagnosis.  Biological factors consisted of age (66-69, 70-74, 75-79, 
and ≥80 years), sex (male/female), and race (white/non-White).  Social factors included marital 
status (married/not married).  Community resources included regions (Northeast, South, West, 
and Northcentral).  Dual Medicare/Medicaid enrollment (yes/no) was  a proxy for low economic 
status.  Years of incident melanoma diagnosis (2012-2015) was used to control for changes in 
Figure 1.1: Adapted 
determinants of health outcomes 




practice patterns.  Aim 3 also included healthcare utilization (visits to primary care physician and 
oncologists). 
Data sources 
Data from multiple sources were used to accomplish the study aims.  
Surveillance, Epidemiology, and End Results (SEER): SEER is a cancer registry and 
provides data on clinical variables related to cancer.  SEER data consists of various files, which 
contain information on patients and cancers. Patient Entitlement and Diagnosis Summary File 
provides information for each person’s date of birth, sex, race, and state of residence.  This file 
also includes information on Medicare eligibility, reason for Medicare entitlement, and health 
maintenance organization (HMO) enrollment by month. In addition, these files also contain 
geographically-based (ZIP code and census tract level) socioeconomic information.  The file 
contains exhaustive information on cancer, such as diagnosis date, cancer stage, tumor size, 
number of positive lymph nodes, and tumor histology. 
SEER-Medicare Claims: Medicare Enrollment File: Medicare is the federally funded 
program that provides health insurance to the elderly, persons with end-stage renal disease, and 
some disabled.  For persons aged 65 and over, nearly 90% are Medicare eligible.  Medicare 
claims provides information on Part A coverage (hospital, skilled nursing facility, hospice and 
some home healthcare), Part B coverage (physician and outpatient services), Part C (HMO 
enrollment, most of whom have fee-for-service coverage), and Part D (prescription drug) 
coverage.  Medicare claims database is the best source of information to estimate Medicare 
payments among the elderly for cancer and other disease states.  To link SEER with Medicare 
data, identifiers contained in the Medicare’s master enrollment file is matched with individual 
identifiers for all persons in their files.  
13 
American Community Survey (ACS) Census Tract Files: The ACS census tract and 
census zip code files were linked to PEDSF files by geographic codes, such as, state and county. 
These files provided information on the census tract median household income and education 
level. 
Area Health Resource File (AHRF): The AHRF is a publicly available data file 
provided by Department of Health and Human Services and contains county, state and national 
files. The AHRF provides more than 6,000 variables for each of the nation's counties. The AHRF 
contains information such as health facilities, health professions, and socioeconomic and 
environmental characteristics. The basic file contains geographic codes and descriptors that may  
be used to link it to other files and to aggregate counties into various geographic groupings. This 
study used the AHRF variables to measure health care infrastructure that can influence the 
detection of multimorbidity, ICI use and expenditures.  
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CHAPTER 2 
2. PREVALENCE AND RISK FACTORS FOR MULTIMORBIDITY IN ELDERLY US 
PATIENTS WITH LATE-STAGE MELANOMA 
2.1. Abstract 
Introduction: Presence of multimorbidity can affect prognosis, treatment, and outcomes 
of individuals with cancer.  However, the prevalence and factors associated with multimorbidity 
among older late-stage melanoma is not well studied. We estimated the prevalence of any type of 
pre-existing multimorbidity (autoimmune disorder (AD), physical health conditions (PHC), and 
mental health conditions (MHC)) among older adults with late-stage melanoma in the United 
States.  We further examined the association of patient-level factors to multimorbidity in late-
stage melanoma. 
Methods: We derived data on older fee-for-service Medicare beneficiaries (age ≥66 
years) diagnosed with late-stage melanoma between 2011 and 2015 (N = 4,519) from the linked 
Surveillance, Epidemiology, and End Results cancer registry and Medicare claims.  We defined 
multimorbidity as the prevalence of two or more chronic conditions prior to the diagnosis of 
melanoma.  We used unadjusted and adjusted logistic regressions to examine the association of 
patient-level factors to multimorbidity. 
Results: An overwhelming majority (85%) of older patients with late-stage melanoma 
had multimorbidity.  Pre-existing PHC multimorbidity (84%) was the most prevalent, followed 
by AD (12%), and MHC (6%).  Age and region were associated with any and PHC 
multimorbidity. Sex, marital status, and region were factors associated with pre-existing AD 
while sex, marital status, and dual eligibility were associated with MHC multimorbidity. 
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Conclusions: Pre-existing multimorbidity was highly prevalent among older individuals 
with late-stage melanoma; prevalence rates and factors associated with multimorbidity varied by 
type of chronic conditions.  This highlights the need for developing systematic approaches to 
optimizing care of older patients with late-stage melanoma and multimorbidity. 
2.2. Introduction 
Melanoma is a form of skin cancer with an alarmingly-rising incidence in the United 
States (US), making it the fifth most common cancer, with the highest occurrence among the 
elderly (≥65 years).2,62,63  Although melanoma accounts for 2% of all skin cancers, late-stage 
melanoma is the most lethal, accounting for 90% of deaths.2  A key factor for treatment of 
patients with melanoma is having a pre-existing chronic condition.  Pre-existing chronic 
conditions are highly prevalent in all cancers and have been shown to affect cancer stage at 
diagnosis, treatment, and outcomes; melanoma being no exception.32,64  The prevalence of 
chronic conditions in patients with melanoma varies from 19% to 80%.33,34  The presence of 
additional chronic conditions prevents physicians from aggressively treating melanoma, thereby 
increasing the risk of mortality.33,34 
As patients age, the number of chronic conditions increases.29  Some studies focused on 
the presence of multimorbidity, defined as the presence of two or more chronic conditions, 
among patients with breast, bladder, and colorectal cancers.65–68  These studies also documented 
high prevalence of multimorbidity and associated adverse outcomes.  However, to date no study 
has exclusively examined multimorbidity in patients with late-stage melanoma perhaps due to 
the poor survival of these patients.  Studies of multimorbidity among late-stage melanoma 
patients are important and needed for reasons stated below. 
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Immune checkpoint inhibitors (ICI) have changed the treatment landscape of late-stage 
melanoma, with significant improvements in survival.6,69  However, pre-existing multimorbidity 
may compete with cancer care because cancer treatment needs to focus not only on mortality but 
also treatment complications and quality of life.70  For example, ICIs affect the immune 
system.18  Patients with pre-existing autoimmune diseases (AD) have weaker immune systems, 
and this may deter their treatment with ICI, due to fears of higher mortality and worse quality of 
life post-treatment.42,71  As ICIs are often used in cancer patients with pre-existing AD seeking 
care in the real-world settings,42,43,72 it is critical to assess the prevalence of pre-existing AD in 
the elderly.  Furthermore, literature also suggests that those with mental health conditions 
(MHCs) may have barriers to cancer care.37  However, most studies on patients with cancer have 
focused only on anxiety and depression; the presence of other MHCs, such as dementia, can also 
lead to less-aggressive cancer treatment because of compromised informed consent and adverse 
effects.38–41  Therefore, estimating the prevalence of any type of multimorbidity can be useful to 
the providers as well as patients.  Including a comprehensive list of MHCs and ADs is necessary 
because studies often include only limited MHCs and no ADs.  In addition, examining factors 
(i.e. risk profile) other than age that may be associated with multimorbidity can help in assessing 
disease burden, surveillance, treatment decisions, and survivorship plans of patients with late-
stage melanoma. 
Therefore, the objectives of the current study are to estimate the prevalence and type of 
multimorbidity prior to the diagnosis of late-stage melanoma and assess the association of 




We adopted a retrospective cohort design.  The cohort consisted of older adults with 
incident late-stage (stage III/IV) melanoma diagnosis based on the American Joint Committee on 
Cancer 7th Edition.  Index date was defined as the date of incident late-stage melanoma 
diagnosis.  Pre-index period was defined as 12 months before incident melanoma diagnosis.  
Multimorbidity, type of multimorbidity, and all independent variables were assessed during the 
pre-index period. The study was exempted by West Virginia University Institutional Review 
Board. 
Data Source 
Surveillance, Epidemiology, and End Results (SEER) cancer registry and Medicare 
claims files were used. The SEER data provided information on clinical variables related to 
cancer (example: stage of cancer at diagnosis); Medicare claims provided information on 
healthcare encounters of the beneficiaries when enrolled and using Medicare covered health 
services. 
Study Population 
We identified 41,848 individuals with incident melanoma diagnosis between 2011 and 
2015 using ICD-O-3 site (C44.0 - C44.9) and histology (8720 – 8790) codes.  Following the 
exclusion of those with local or regional (stage I/II) melanoma, non-incident melanoma, below 
the age of 66 years, not continuously enrolled in Medicare part A and Part B during the pre-index 
period, and diagnosed with late-stage cancer during autopsy, the final analytical cohort 
comprised 4,519 individuals with late-stage melanoma. 
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Measures 
Dependent variables: Any, PHC, MHC, and AD multimorbidity 
Multimorbidity was defined as the presence of ≥2 chronic conditions prior to the 
diagnosis of incident late-stage melanoma. We used the list of chronic conditions developed by 
the Multiple Chronic Conditions working group within the US Department of Health and Human 
Services Office of Assistant Secretary of Health.73  The list was developed based on the 
conditions that met the definition of chronicity, are prevalent, and are potentially amenable to 
public health.  Based on the current challenges with ICIs, pre-existing AD was added, which 
were identified from a list of 131 conditions provided by the American Autoimmune-Related 
Disease Association (Appendix 7.1).74  All these conditions were identified with International 
Classification of Diseases (ICD), 9th Edition. 
Physical Health Conditions (PHC) consisted of pre-existing AD, arthritis, asthma, 
coronary artery disease, cardiac arrhythmias, diabetes, congestive heart failure, chronic kidney 
disease, chronic obstructive pulmonary disease (COPD), hepatitis, hyperlipidemia, hypertension, 
human immunodeficiency virus, obesity, osteoporosis, and stroke. 
To explore the PHC most prevalent among those with multimorbidity, we created a 
taxonomy of PHC.  The groups were: cardiovascular diseases (CVD - coronary artery disease, 
cardiac arrhythmias, congestive heart failure, and hypertension), endocrine diseases (diabetes, 
hyperlipidemia, and obesity), musculoskeletal diseases (arthritis, osteoporosis, and pre-existing 
AD), and respiratory diseases (asthma and COPD). 
Mental health conditions (MHC) consisted of anxiety, bipolar disorder, depression, 
psychoses, schizophrenia, and substance abuse. 
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We also added PHC groups (CVD, endocrine, musculoskeletal, and respiratory diseases) 
and MHCs to explore any multimorbidity using combinations of dyads (e.g. CVD /endocrine 
diseases, MHC/respiratory diseases) and triads (e.g. CVD/endocrine diseases/MHC). 
Indices of pre-existing conditions for each of the categories (PHC, MHC, and AD) were 
also created.  These were derived by counting the number of conditions in each of the groups; 
PHC index ranged from 0-13, MHC index from 0-5, and AD index from 0-6. 
Independent variables 
These were identified at the pre-index period and included biological and social factors, 
community resources, socio-economic status, and year of diagnosis.  Biological factors consisted 
of age (66-69, 70-74, 75-79, and ≥80 years), sex (male/female), and race (white/non-white).  
Social factors included marital status (married/not married).  Community resources included 
regions (Northeast, South, West, and Northcentral).  Dual Medicare/Medicaid enrollment 
(yes/no) was used as a proxy for low economic status.  Years of incident melanoma diagnosis 
(2012-2015) was used to control for changes in practice patterns. 
Statistics 
Chi-square tests were used to identify significant unadjusted associations of individual 
characteristics to multimorbidity. Multivariable logistic regressions were performed to determine 
the factors associated with multimorbidity.  Parameter estimates are presented as adjusted odds 
ratios (AORs) after adjusting for all independent variables, with their corresponding 95% 
confidence intervals (CI); p ≤ 0.05 was considered statistically significant.  All analyses were 
conducted using SAS 9.4 (SAS Institute Inc.). 
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2.4. Results 
The study population was predominantly male (64.2%), White (96.1%) and ≥70 years 
(70.4%).  The mean number of chronic conditions (including PHCs, MHCs and ADs) was 4.26 
with median of 4.0.  The mean number of PHCs was 3.98 with median of 4.0.  The prevalence of 
any PHC was 92.3%; MHC was 20.8% and AD was 28.7%.  The most prevalent pre-existing 
condition was CVD (78%) followed by endocrine diseases (72%). 
Multimorbidity patterns 
Multimorbidity was highly prevalent (85%) in the US elderly with late-stage melanoma.  
The prevalence of multimorbidity varied by type of chronic conditions: 84% had PHC 
multimorbidity, 12% had AD multimorbidity, and 6% had MHC multimorbidity. 
Among those with any multimorbidity, the most prevalent dyad combination was 
endocrine and musculoskeletal diseases combination (21.7%) followed by CVD and endocrine 
disease combination (20.3%).  Among triads, CVD, endocrine, and musculoskeletal disease 
combination (22.6%) was the most prevalent followed by endocrine, MHC, and musculoskeletal 
disease combination (7%). 
Factors associated with any multimorbidity 
In unadjusted analyses, characteristics of individuals with and without multimorbidity 
differed by age and region (Table 2.1).  A significantly higher proportion of Medicare 
beneficiaries aged ≥80 years had multimorbidity compared to those in the age group 65-69 years 
(89.4% versus 77.1%, p < .0001).  Multivariable logistic regression on any multimorbidity 
showed similar results (Table 2.1).  Older adults in the age group 70-74 years (AOR, 1.41; 
95%CI, 1.12, 1.76), 75-79 years (AOR, 1.84; 95%CI, 1.44, 2.35) and ≥80 years (AOR, 2.55; 
95%CI, 2.04, 3.18) were more likely to have pre-existing multimorbidity compared to those in 
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the age group 65-69 years.  Older adults residing in the Northcentral (AOR, 0.69; 95%CI, 0.49, 
0.96) and Western (AOR, 0.65; 95%CI, 0.51, 0.83) SEER regions were less likely to have any 
multimorbidity compared to residents in the Northeastern parts. 
Factors associated with PHC multimorbidity 
In unadjusted analyses, characteristics of individuals with and without PHC 
multimorbidity differed by age and region (Table 2.2).  Individuals with PHC multimorbidity 
had significantly higher proportion of those aged ≥70 years and residing in Northeastern regions 
compared to those without PHC multimorbidity.  Multivariable logistic regression on PHC 
multimorbidity showed similar results (Table 2.3).  Older adults in the age group 70-74 years 
(AOR, 1.42; 95%CI, 1.13, 1.77), 75-79 years (AOR, 1.81; 95%CI, 1.42, 2.30) and ≥80 years 
(AOR, 2.47; 95%CI, 1.99, 3.06) were more likely to have pre-existing multimorbidity compared 
to those in the age group 65-69 years.  Older adults residing in the Northcentral (AOR, 0.65; 
95%CI, 0.47, 0.90) and Western (AOR, 0.67; 95%CI, 0.53, 0.85) SEER regions of the US were 
less likely to have PHC multimorbidity compared to residents in the Northeastern region. 
Factors associated with AD multimorbidity 
In unadjusted analyses, characteristics of individuals with and without AD 
multimorbidity differed by sex and region (Table 2.2).  A significantly higher proportion of 
females and residing in Northcentral SEER regions compared had AD multimorbidity compared 
to men and those residing in Northeastern regions.  Multivariable logistic regression on AD 
multimorbidity (Table 2.3) confirmed unadjusted associations; females (AOR, 1.81; 95%CI, 
1.48, 2.22) were nearly two times as likely to have AD multimorbidity compared to older males.  
Unmarried older adults (AOR, 0.79; 95%CI, 0.65, 0.97) and those residing in southern SEER 
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regions (AOR, 0.58; 95%CI, 0.42, 0.80) were less likely to have AD multimorbidity compared to 
married elderly and residents in the Northeastern regions. 
Factors associated with MHC multimorbidity 
In unadjusted analyses, characteristics of individuals with and without MHC 
multimorbidity differed by sex, marital status, and dual eligibility (Table 2.2).  Elderly with 
MHC multimorbidity had significantly higher proportion of females, unmarried, and lower 
income status.  Multivariable logistic regression on MHC multimorbidity showed similar results 
(Table 2.3).  Older females (AOR, 1.88; 95%CI, 1.46, 2.44) and those not married (AOR, 1.85; 
95%CI, 1.41, 2.44) were more likely to have MHC multimorbidity compared to older males and 
those married.  Older adults with lower income status (AOR, 3.33; 95%CI, 2.14, 5.19) were three 
times more likely to have MHC multimorbidity compared to those with higher income status. 
2.5. Discussion 
There is sparse information on prevalence of multimorbidity among individuals with 
melanoma, with no studies focusing on the elderly with late-stage melanoma.  This is the first 
study to explore the prevalence and factors associated with the presence and type of 
multimorbidity among older adults with late-stage melanoma in the US.  We found that 4 in 5 
older adults with late-stage melanoma had pre-existing multimorbidity.  Our estimates are higher 
than those found in non-US studies.  For example, a Danish study reported multimorbidity in 9% 
of patients with melanoma.33  This study included adults (>18 years) and all stages of melanoma.  
In contrast, a German study reported multimorbidity in 57% of patients with melanoma.  The 
difference in estimated prevalence rates among these studies may be due to the differences in the 
study population (all stages as opposed to late-stage and older adults as opposed to adults 18 
years or older) and time-period (pre-existing versus co-existing conditions). 
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The most common comorbid conditions in our study were CVD, endocrine, and 
musculoskeletal diseases or a combination of the three in dyads and triads.  This is not surprising 
given that CVD, endocrine, and musculoskeletal diseases are highly prevalent in older adults.75,76  
These diseases and cancer share modifiable risk factors, with some studies stating a bidirectional 
relationship between them.77–79  As heart disease, diabetes, and malignant cancers are among the 
top five leading causes of age-adjusted mortality,80 healthcare providers managing patients with 
late-stage melanoma may need to routinely monitor for the presence of these conditions and 
coordinate their care with the primary care physicians. 
Among risk factors for any multimorbidity, age is well-established, with studies reporting 
that the number of chronic conditions increases with age,29,33 a trend noted in our study as well.  
Increasing number of chronic conditions led to late-stage cancer detection, as both the patient 
and the physician were distracted by the pre-existing conditions.81  Adding increasing age to the 
mix resulted in less aggressive treatment and a dismal chance of entering a clinical trial, as 
physicians had to grapple with physical frailty and polypharmacy as well in these patients.33,81  
Therefore, oncologists should optimize the treatment of aging patients with multimorbidity to 
improve their outcomes. 
Regions, namely Northcentral and Western SEER regions, were associated with lower 
odds of having multimorbidity.  There are no exhaustive studies on SEER geographical 
disparities in late-stage melanoma cancer patients, and further research is needed to explain these 
results. 
Our study also examined type of multimorbidity in terms of PHC, AD, and MHC.  Risk 
factors for PHC multimorbidity were similar to any multimorbidity, perhaps because PHC was 
more prevalent than MHC, making up the bulk of multimorbidity index.  Among the PHC, we 
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further explored the prevalence of pre-existing AD among older patients.  In 2014, the 
prevalence of pre-existing AD among individuals with metastatic melanoma was 20%.36,82  Our 
study echoed those findings among the elderly as well.  Similar to a previous study on patients 
with metastatic melanoma and AD, our study also notes sex and region as a risk factor for AD 
multimorbidity.36  In addition, this study also notes the presence of social support in the form of 
spouses as a risk factor for AD multimorbidity.  Spouses are an important source of social 
support for patients with any chronic condition.83  Therefore, patients with multiple AD are more 
dependent on that social support to manage their conditions.83  Oncologists should consider these 
risk factors when deciding if a drug acting via the immune system is the best course of treatment 
for older patients. 
Consistent with other studies, we observed 30% of older adults with late-stage melanoma 
were diagnosed with any MHC.84,85  Similar levels of MHC were also found in individuals with 
late-stage breast,38 colorectal,39 and prostate cancer.40  Sex as a risk factor was also observed 
with MHC multimorbidity, perhaps because MHC are more prevalent in females compared to 
males.86,87  In addition, lack of social support was a risk factor for MHC multimorbidity.  Social 
deprivation is a known risk factor for MHC among patients with cancer.88,89  We also observed 
that dual eligibility was a risk factor for having MHC multimorbidity.  Individuals with 
melanoma having Medicaid had worse prognosis compared to uninsured and non-Medicaid 
individuals, pointing to the importance of socioeconomic status in melanoma care.90  These risk 
factors should be assessed in order to reduce further psychological distress and devise 
appropriate follow-up interventions. 
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2.6. Strengths and limitations 
The present study has several limitations.  First, SEER does not contain information on 
individual behavior such as smoking status, alcohol consumption, or functional status, all of 
which can further affect the risk of having multimorbidity.  Second, we did not have access to 
individual-level socioeconomic factors, such as education and income.  Third, we could not 
determine the severity of the conditions.  Despite these limitations, this study has several 
strengths.  Although few studies on comorbid conditions in individuals with melanoma exist, 
they did not focus on late-stage melanoma, perhaps because the prognosis was poor with low 
chances of survival.91  Therefore, prognostic burden of multimorbidity in such individuals was 
deemed less important.91  However, newer therapies such as ICIs will improve survivorship of 
patients with late-stage melanoma.  Therefore, information on the prevalence and type of 
multimorbidity in such individuals can help both physicians and patients in choice of cancer 
treatment, survivorship plans, and quality of life care.  We included an exhaustive list of PHC 
and MHC, including pre-existing AD. 
2.7. Conclusions 
Nearly 4 in 5 older adults with late-stage melanoma had any multimorbidity.  The 
prevalence of multimorbidity varied by type of conditions with lowest in MHC and highest in 
PHC.  One in 10 older adults with late-stage melanoma had AD multimorbidity, suggesting 
challenges to the management and decisions for treatment.  Cardiovascular, endocrine, and 
musculoskeletal diseases were the most commonly occurring comorbid conditions, which share 
risk factors with cancer.  While the risk factors for any multimorbidity were age and region, they 
varied depending on the type of multimorbidity.  Therefore, surveillance of type of 
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multimorbidity in clinical care should routinely be conducted to properly decide the treatment 
and follow-up care among older patients with late-stage melanoma.  
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Table 2.1 
Percent with Immune Checkpoint Inhibitor (ICI) use by Selected Patient-level 
Characteristics among Older Adults (age >65 years) with Incident Late-stage 
Melanoma during 2012 and 2015 
Linked Surveillance, Epidemiology, and End Results and Medicare Claims Database 
 Variables 
ICI No ICI   
N (%) N (%) p-value Significance 
ALL 252 (5.6) 4,267 (94.4)   
Multimorbidity     
 Yes 211 (5.5) 3,622 (94.5) 0.62  
 No 41 (6.0) 645 (94.0)   
Year of diagnosis     
 2012 35 (3.2) 1,060 (96.8) 0.0008 *** 
 2013 63 (5.8) 1,026 (94.2)   
 2014 74 (6.4) 1,090 (93.6)   
 2015 80 (6.8) 1,091 (93.2)   
Age     
 66 to 69 years 62 (6.8) 851 (93.2) 0.0004 *** 
 70 to 74 years 76 (7.6) 929 (92.4)   
 75 to 79 years 45 (5.0) 860 (95.0)   
 ≥80 years 69 (4.1) 1,627 (95.9)   
Sex     
 Female 72 (4.5) 1,545 (95.5) 0.014 * 
 Male 180 (6.2) 2,722 (93.8)   
Race     
 Whites 239 (5.5) 4,103 (94.5) 0.29  
 Non-Whites 13 (7.3) 164 (92.7)   
Marital Status     
 Married 163 (7.3) 2,057 (92.7) <0.0001 *** 
 Not married 89 (3.9) 2,210 (96.1)   
Dual Medicare/Medicaid eligibility   
 Yes 17 (10.0) 153 (90.0) 0.0104 * 
 No 235 (5.4) 4,114 (94.6)   
Regions     
 Northeast 64 (7.9) 748 (92.1) 0.0186 * 
 South 49 (5.1) 916 (94.9)   
 North Central 24 (5.1) 451 (94.9)   
 West 115 (5.1) 2,152 (94.9)   
Note: Based on 4,519 older adults with incident late-stage (Stage III/IV) melanoma 
continuously enrolled in Medicare Part A & B fee-for service programs 12 months prior 




Percent with Type of Multimorbidity by Selected Patient-level Characteristics 
Older Adults (age ≥65 years) with Incident Late-stage Melanoma during 2011 and 2015 
Linked Surveillance, Epidemiology, and End Results and Medicare Claims Database   
PHC Multimorbidity AD Multimorbidity MHC Multimorbidity 
   % Yes % No % Yes % No % Yes % No 
Year of diagnosis      
 2012 83.7 16.3 10.4 89.6 5.0 95.0 
 2013 82.8 17.2 9.6 90.4 5.1 94.9 
 2014 85.8 14.2 9.1 90.9 6.4 93.6 
 2015 83.0 17.0 10.7 89.3 6.9 93.1 
Agea       
 65 to 69 years 76.0 24.0 8.8 91.2 6.6 93.4 
 70 to 74 years 81.9 18.1 9.6 90.4 5.8 94.2 
 75 to 79 years 85.2 14.8 9.8 90.2 6.0 94.0 
 ≥80 years 88.6 11.4 10.9 89.1 5.5 94.5 
Sexb,c       
 Female 84.2 15.8 13.2 86.8 8.8 91.2 
 Male 83.7 16.3 8.1 91.9 4.2 95.8 
Race       
 White 83.9 16.1 10.1 89.9 5.9 94.1 
 Non-Whites 83.1 16.9 6.8 93.2 5.6 94.4 
Marital statusc       
 Married 84.2 15.8 10.4 89.6 3.9 96.1 
 Not married 83.6 16.4 9.5 90.5 7.8 92.2 
Regiona,b       
 Northeast 87.4 12.6 11.9 88.1 6.3 93.7 
 South 85.7 14.3 7.2 92.8 6.0 94.0 
 North central 82.5 17.5 13.5 86.5 8.0 92.0 
 West 82.1 17.9 9.7 90.3 5.2 94.8 
Dual Medicare/Medicaid Enrollment c     
 Yes 86.5 13.5 9.4 90.6 17.1 82.9 
  No 83.8 16.2 10.0 90.0 5.4 94.6 
Note: Based on 4,519 older adults with incident late-stage (Stage III/IV) melanoma, continuously enrolled in 
Medicare Parts A and B fee-for service programs 12 months prior to incident cancer diagnosis. 
 
AD: Autoimmune diseases; MHC: Mental health conditions; PHC: Physical health conditions 
 
a represents significant group differences in presence or absence of PHC multimorbidity; b represents significant 
group differences in presence or absence of AD multimorbidity; c represents significant group differences in 




Adjusted Odds Ratios (AOR) and 95% Confidence Intervals (CI) from 
Separate Multivariable Logistic Regressions on Type of Multimorbidity 
Older Adults (age ≥65 years) with Incident Late-stage Melanoma during 2011 and 2015 
Linked Surveillance, Epidemiology, and End Results and Medicare Claims Database 
    PHC Multimorbidity  AD Multimorbidity MHC Multimorbidity  
   AOR 95% CI Prob AOR 95% CI Prob AOR 95% CI Prob 
Year of diagnosis            
 2012 1.00 [ 0.80 ,  1.26]   0.95 [ 0.73 ,  1.25]   0.73 [ 0.51 ,  1.05] 
 
 2013 0.95 [ 0.76 ,  1.19]   0.88 [ 0.67 ,  1.17]   0.75 [ 0.53 ,  1.08] 
 
 2014 1.21 [ 0.96 ,  1.52]   0.82 [ 0.62 ,  1.08]   0.96 [ 0.69 ,  1.34] 
 
 2015 [ref] 
   [ref]    [ref]   
Age            
 65 to 69 years [ref] 
   [ref]    [ref]   
 70 to 74 years 1.42 [ 1.13 ,  1.77] 0.002 1.11 [ 0.81 ,  1.52]   0.92 [ 0.63 ,  1.35] 
 
 75 to 79 years 1.81 [ 1.42 ,  2.30] <0.001 1.16 [ 0.84 ,  1.59]   0.95 [ 0.65 ,  1.40] 
 
 ≥80 years 2.47 [ 1.99 ,  3.06] <0.001 1.22 [ 0.92 ,  1.62]   0.74 [ 0.53 ,  1.04] 
 
Sex            
 Female 1.02 [ 0.86 ,  1.21]   1.81 [ 1.48 ,  2.22] <0.001 1.88 [ 1.46 ,  2.44] <0.001 
 Male [ref] 
   [ref]    [ref]   
Race            
 White [ref] 
   [ref]    [ref]   
 Non-Whites 1.03 [ 0.68 ,  1.55]   0.62 [ 0.34 ,  1.14]   0.63 [ 0.32 ,  1.24] 
 
Marital status            
 Married [ref] 
   [ref]    [ref]   
 Not married 0.91 [ 0.77 ,  1.07]   0.79 [ 0.65 ,  0.97] 0.03 1.85 [ 1.41 ,  2.43] <0.001 
Region            
 Northeast [ref] 
   [ref]    [ref]   
 South 0.89 [ 0.68 ,  1.18]   0.58 [ 0.42 ,  0.80] 0.001 0.93 [ 0.62 ,  1.38] 
 
 North central 0.65 [ 0.47 ,  0.90] 0.009 1.13 [ 0.80 ,  1.59]   1.42 [ 0.91 ,  2.21] 
 
 West 0.67 [ 0.53 ,  0.85] 0.001 0.82 [ 0.63 ,  1.06]   0.79 [ 0.56 ,  1.12] 
 
Dual Medicare /Medicaid Enrollment          
 Yes 1.31 [ 0.82 ,  2.07]   0.99 [ 0.58 ,  1.69]   3.33 [ 2.14 ,  5.19] <0.001 
 No [ref] 
  [ref]   [ref]   
Note: Based on 4,519 older adults with incident late-stage (Stage III/IV) melanoma continuously enrolled in 
Medicare Parts A and B fee-for-service programs 12 months prior to incident cancer diagnosis. 
 




3. FACTORS ASSOCIATED WITH IMMUNE CHECKPOINT INHIBITOR USE 
AMONG OLDER PATIENTS WITH LATE-STAGE MELANOMA 
3.1. Abstract 
Background:  Improvement in overall survival by immune checkpoint inhibitors (ICI) 
treatment in clinical trials encourages their use for late-stage melanoma.  However, in the real-
world, heterogeneity of population, such as elderly with multimorbidity, may lead to a slower 
diffusion of ICIs.  The objective of this study was to examine the association of multimorbidity 
and other factors to ICI use among older patients with late-stage melanoma using real world data. 
Methods:  A retrospective cohort study design with a 12-month baseline and follow-up 
period was adopted with data from the linked Surveillance, Epidemiology, and End Results 
cancer registry/Medicare database.  Older patients (>65 years) with late-stage (stage III/IV) 
melanoma diagnosed between 2012 and 2015 were categorized as with or without 
multimorbidity (presence of two or more chronic conditions) and ICI use was identified in the 
post-index period.  Chi-square tests and logistic regression were used to evaluate factors 
associated with ICI use. 
Results:  In the study cohort, 85% had multimorbidity, 18% received any treatment 
(chemotherapy, radiation, and/or ICI), and 6% received ICI.  Only 5.5% of older patients with 
multimorbidity and 6% without multimorbidity received ICIs.  Younger age, presence of social 
support, lower economic status, residence in northeastern regions, and recent year of diagnosis 
were significantly associated with ICI use; however, multimorbidity, sex, and race were not 
associated with ICI use. 
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Conclusions:  In the real-world clinical practice, only one in 18 older adults with late 
stage melanoma received ICI, suggesting slow pace of diffusion of innovation.  However, 
multimorbidity was not a barrier to ICI use. 
3.2. Introduction 
Newer therapies, namely immune checkpoint inhibitors (ICIs) with a unique mechanism 
of action and unknown side effect profile,92 have significantly increased the survival prognosis 
for adults with late-state melanoma.19,22,93  The first ICI was approved in 2011 by the United 
States (US) Food and Drug Administration and has since been recommended as the first-line 
treatment for late-stage melanoma by the National Cancer Comprehensive Network (NCCN) 
guidelines.42,93  These recommendations were based on the evidence presented in randomized 
clinical trials (RCTs), which have strict inclusion and exclusion criteria.19,20,72  These stringent 
criteria, while beneficial to ensure patient safety, do not capture the heterogeneity of various 
patient subpopulations. 
This lack of information on heterogeneity of treatment effects may be a reason that 
despite being around for nearly a decade, the uptake of ICI in the real-world setting is dismal.94  
One of the patient subpopulations where evidence on use of ICI is lacking is the elderly.  
Although utility of ICI in elderly patients with late-stage melanoma is debated, data from studies 
have shown that these therapies are well tolerated in the elderly.95–97  Older patients are also 
known to have multiple chronic conditions (also known as multimorbidity), which are often not 
taken into account by the guidelines.95,96,98  There are no studies to-date examining the 
association of multimorbidity on treatment with ICI among older individuals with late-stage 
melanoma.  Presence of multimorbidity leads to less aggressive treatment with existing 
modalities (such as chemotherapy and radiation) due to fear of worsening other conditions.32,33,35  
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Older patients with multimorbidity are the norm rather than exception in clinical practices.29  
Therefore, evaluating the association of multimorbidity to ICI use in real-world setting may help 
healthcare providers personalize these treatments for their older patients. 
In addition, disparities in the receipt of ICI are unknown.  Studies on other cancers have 
shown some subgroups may be less likely to receive treatment.  For example, age and racial 
disparities on treatment received was reported among older patients with late-stage pancreatic 
adenocarcinoma.46  Patients below the age of 80 years and White non-Hispanics were more 
likely to receive treatment than those above 80 years of age and other race/ethnicity.46  Similarly, 
a study among older patients with bladder cancer reported better survival among married patients 
than unmarried ones, because of greater likelihood of receiving treatment.47  Underinsured 
patients with late-stage melanoma were more likely to receive treatment at lower immunotherapy 
prescribing hospitals.48  With evident disparities in receipt of treatment, it is critical to know 
whether some subgroups lag in the diffusion of innovative therapies like ICIs, so that oncologists 
and patients alike can make informed decisions when considering ICIs as the treatment option.  
Therefore, the objective of this study is to examine the association of multimorbidity and other 
factors to ICI use that cover years from the initial introduction (i.e. 2011) to 2015 among older 
patients with late-stage melanoma. 
3.3. Methods 
Study Design 
This was a retrospective cohort design with a 12-month baseline (pre-diagnosis) and 
12-month follow-up (post-diagnosis) period.  Diagnosis date of late-stage (stage III/stage IV) 
melanoma diagnosis was used to define pre- and post-diagnosis periods.  Multimorbidity and all 
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independent variables were assessed in the baseline period while treatments (chemotherapy, 
radiation, ICI) received were assessed in the follow-up period. 
Data Source 
This study was conducted using the Surveillance, Epidemiology, and End Results 
(SEER) cancer registry linked with fee-for-service Medicare claims.  Information on clinical 
variables related to cancer (such as stage of cancer at diagnosis) was obtained from SEER data, 
while information on healthcare encounters of beneficiaries when enrolled and using Medicare 
covered health services was obtained from Medicare claims. 
Study Population 
Incident melanoma diagnosis between 2011 and 2015 was identified using ICD-O-3 site 
codes (C44.0 – C44.9) and ICI-O-3 histology codes (8720 – 8790).  Late-stage (stage III/IV) of 
melanoma was identified based on the TNM classification using American Joint Committee on 
Cancer 7th Edition.  The final cohort comprised of 4,519 patients with late-stage melanoma 
following exclusion of those with local or regional (stage I/II) melanoma, non-incident 
melanoma, ages 66 years and below, not continuously enrolled in Medicare part A and part B 
during pre-index period, and diagnosed with late-stage cancer during autopsy. 
Measures 
Dependent variable: ICI use 
The study outcome, ICI use, was identified in the post-diagnosis period.  The ICIs 
approved for late-stage melanoma treatment include ipilimumab, nivolumab, and 
pembrolizumab, which were identified using healthcare common procedure coding system 
(HCPCS) codes (J9228, J9299, J9271). 
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Independent variables 
Multimorbidity: Presence of two or more chronic conditions in the pre-diagnosis period 
was defined as multimorbidity in this study.  These conditions were obtained from a list of 18 
chronic conditions developed by Multiple Chronic Conditions working group within the US 
Department of Health and Human Services Office of Assistant Secretary of Health.  Pre-existing 
autoimmune diseases were also added to the list based on the current challenges with ICI use in 
patients with these conditions.73  All these conditions were identified with International 
Classification of Diseases (ICD), 9th Edition. 
Treatment with chemotherapy and radiation was also determined in the post-index period.  
Chemotherapy and radiation claims were identified using procedure codes, HCPCS codes, and 
revenue center codes (see Appendix 7.2). Overlapping procedure codes for chemotherapy and 
ICI (96413, 96415) were excluded to avoid confusion. 
Biological factors consisted of age (66-69 years, 70-74 years, 75-79 years, and ≥80 
years), sex (male/female), and race (white/non-white).  Social factors included marital status 
(married/not married).  Community resources included regions (Northeast, South, West, and 
North Central).  Dual Medicare/Medicaid enrollment (yes/no) was used as a proxy for low 
economic status.  Years of incident melanoma diagnosis (2012-2015) was used to control for 
changes in practice patterns. 
Statistical Analysis 
Chi-square tests were used to identify significant unadjusted associations of individual 
characteristics to ICI use. Multivariable Logistic regressions were performed to determine the 
association of multimorbidity, year of diagnosis, age, sex, race/ethnicity, marital status, dual 
eligibility, and region with ICI use.  Parameter estimates are presented as adjusted odds ratios 
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(AORs) after adjusting for all independent variables, with their corresponding 95% confidence 
intervals (CI); p ≤ 0.05 was considered statistically significant.  All analyses were conducted 
using SAS 9.4 (SAS Institute Inc.). 
3.4. Results 
The study population comprised predominantly of males (64.2%), Non-Hispanic Whites 
(96.1%) and those 70 years or older (70.4%).  About 85% of the older adults had multimorbidity, 
18% received any treatment, and 6% received ICI.  In the study cohort, 5.5% of patients with 
multimorbidity and 6% of patients without multimorbidity received ICI.  The characteristics of 
those who received and did not receive ICI differed by all variables except the presence of 
multimorbidity (p=0.62) and race (p=0.29) (Table 3.1). 
Factors associated with ICI use: Unadjusted Logistic Regression on ICI use 
Table 3.2 presents the unadjusted odds ratio (OR), AORs, and 95% CIs of all 
independent variables included in the study from separate logistic regressions on ICI use. In the 
unadjusted regressions, year of diagnosis, age, sex, marital status, and dual eligibility were 
significantly associated with ICI use. 
Factors associated with ICI use: Multivariable Logistic Regression on ICI use 
Patients in the lower age groups (66 to 69 years and 70 to 74 years) had significantly 
higher odds of receiving ICIs than those 80 years and above (AOR=1.65, 95%CI=1.15, 2.36; 
AOR=1.81, 95%CI=1.28, 2.54 respectively).  Patients who were married (AOR=1.92, 
95%CI=1.46, 2.52), resided in the Northeastern SEER regions (AOR=1.75, 95%CI=1.26, 2.41), 
and had dual eligibility (AOR=2.42, 95%CI=1.40, 4.19) were more likely to receive ICIs than 
the comparison groups: those who were not married, residing in SEER Western regions, and did 
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not have dual eligibility.  Patients diagnosed in 2012 (AOR=0.42, 95%CI=0.28, 0.63) were less 
likely to receive ICI than those diagnosed in 2015. 
Multimorbidity was not significantly associated with ICI in fully adjusted models.  In the 
fully adjusted model, sex and race were not significantly associated with ICI use. 
3.5. Discussion 
The treatment landscape for late-stage melanoma remained unchanged for decades before 
the introduction of ICIs in 2011.  The median overall survival with traditional treatments 
(chemotherapy and/or radiation) is 6 to 8 months.99,100  Due to poor prognosis for survival, many 
patients may not receive treatment, as observed in this study.  An overwhelming majority (82%) 
of the cohort did not receive any treatment for their late-stage melanoma.  Post-late stage 
melanoma diagnosis treatment rates (18%) observed in this study is consistent with a published 
study (22%).101  In this published study, the authors noted 22% initiated treatment after the 
disease progression while 51% started treatment before late-stage melanoma diganosis.101 
Although ICIs have been around for nearly a decade, evidence on the treatment pattern in 
the real world is just emerging.  Recent studies exploring the real-world treatment patterns 
among all adults for late-stage melanoma reported that only 34-37% of the patients received ICI 
as the first-line treatment, despite the recommendation by the NCCN guidelines.25,102,103  The 
rates of treatment with ICI in our study is very low (6%).  A plausible reason for the low rate can 
be due to the differences in population studied.  Our study focused on older adults with 85% 
having pre-existing multimorbidity who may be at high risk for poor survival prognosis.  As 
evidence is still emerging on the side effect profile of ICIs compared to existing modalities,104 
oncologists may be cautious in using ICI among older patients with late-stage melanoma. 
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This study observed that an overwhelming majority of patients had pre-existing 
multimorbidity, no different than other cancer types.32,105  As RCTs of ICIs typically exclude 
patients with multimorbidity, 106 evidence on the association of multimorbidity to ICI use is not 
available.  This is the first study to report the use of ICI among older patients with 
multimorbidity status.  In this study, those with multimorbidity were as likely to receive ICI as 
those without, suggesting that multimorbidity was not a barrier in the receipt of ICI.  While the 
rationale for this was not explored further, plausible reasons are discussed.  Recent studies using 
SEER-Consumer Assessment of Healthcare Providers and Systems suggest that patients with 
multimorbidity and cancer have better communication with their providers and rated specialties 
better than those without multimorbidity.107  It has also been reported that elderly Medicare 
beneficiaries with multimorbidity are equally likely to trust their doctors for their care,108 
suggesting that multimorbidity may not be a barrier to novel life-saving therapies. 
This is the first study to the best of our knowledge that explored the factors associated 
with ICI use among the elderly with late-stage melanoma.  In this study, compared to patients 
80 years and older, those between the ages of 66 and 74 years were more likely to receive ICIs.  
However, published studies did not find additional adverse events or  difference in overall 
survival in patients between 80 to 100 years versus those between 65 to 79 years, when treated 
with ICIs.96  Oncologists may exercise caution in active treatment of cancer among old-old (age 
> 80 years), because side effects can occur more often and in greater severity in this age 
group.105,109,110  Furthermore, higher rates of pre-existing chronic conditions in this age group 
may also warrant cautious active cancer treatment.  In our study, nearly 90% of those 80 years or 
older had pre-existing multimorbidity compared to only 82% among 65 to 79 years.  Due to 
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small cell sizes, we were unable to empirically test the interaction of old-old with multimorbidity 
on ICI use in our study. 
In this study, social support, measured with the proxy (i.e. marital status), was 
significantly associated with ICI use.  Presence of social support have shown lesser 
psychological distress among patients with cancer and more enthusiasm about getting treatment, 
even if the disease is terminal.111,112  Therefore, these patients are more accepting of newer 
treatments.  It is plausible that shared decision making with the patient and their 
caregivers/support system may increase the use of novel therapies in real-world settings. 
Regional variations were also observed in our study, with older patients residing in 
Northeastern SEER regions having higher rates of ICI use.  The reasons for differential adoption 
of newer treatments across the US regions is complex.  Although to date, no study has examined 
regional disparities in ICI use among late-stage melanoma patients, few reasons for regional 
disparities based on evidence from the adoption of new medical treatments and new technologies 
are speculated here.  The US states with higher population density may also have greater number 
of highly skilled professionals.  In addition, these states tend to have policies that provide more 
opportunities to capitalize on innovations and are more likely to adopt innovations faster.113,114  
Based on these factors, states in the Northeastern region including New York, Connecticut, and 
Massachusetts, had the highest innovation scores compared to other US states.113  In addition, 
key opinion leaders, who also lead many RCTs, play an important role in the diffusion of 
innovation.115  A study reported that such opinion leaders were based in urban areas, most of 
them in the Northeastern regions such as New York City and Boston.115  These leaders 
encouraged use of innovative therapies in real-world settings.115  Healthcare providers in various 
US regions should, therefore, evaluate the political influences in driving their prescribing 
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practices and work with local opinion leaders in finding ways to improve adoption of newer 
therapies among patients. 
In this study, dual Medicaid/Medicare eligibility was positively associated with ICI use.  
Previous studies have reported that dually eligible beneficiaries are less likely than Medicare-
only beneficiaries to receive prostate or breast cancer treatment.116  In a study of lung cancer 
patients, dual eligibility status was associated with longer duration of treatment.117  Recent 
studies on late-stage melanoma reported that patients with Medicaid were less likely to receive 
ICIs and those with Medicare were as likely to receive ICIs as patients with commercial 
insurance.118–120  Thus, the receipt of ICI may be driven more by Medicare than Medicaid. 
Year of diagnosis was significantly associated with ICI use, with those diagnosed in 
earlier years being less likely to use ICIs.  This may be because of few completed RCTs at the 
time and only one ICI (ipilimumab) approved for the treatment before 2014.  Therefore, the data 
to support the safety and efficacy of ICI had not been widely been disseminated.  In addition, the 
diffusion of innovation takes substantial time.94  Rather than rely on communication of a medical 
innovation, most physicians adopted the innovation after watching their colleagues use them.121  
This is especially true when contemplating use in populations excluded in the RCTs,121 such as 
older patients with multimorbidity.  Although the use of ICI as first-line treatment in late-stage 
melanoma was added in NCCN guideline in 2012, studies on the use of ICI in real-world settings 
remain limited. 
3.6. Strengths and limitations 
The findings of this study should be interpreted considering its limitations.  First, the 
reasons for not receiving any treatment in older patients was unknown.  Though disparities in ICI 
use were observed, we are unable to evaluate whether these disparities are due to patient 
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preferences or shared decision-making of providers and patients.  Such information could direct 
healthcare providers on measures that can be taken to enhance the adoption of ICIs.  Second, 
individual-level socioeconomic factors, such as education and income, which may be associated 
with ICI use, were not available to us.  Third, information on severity of co-existing illnesses 
may have provided insights into whether the intake is low because of competing demands that 
may confer high mortality risk and may have precluded the use of ICI.  Despite these limitations, 
the study has several strengths.  No study to-date has focused on treatment of older adults with 
multimorbidity and late-stage melanoma.  With a high prevalence, oncologists are bound to 
encounter such patients on a daily basis. This study provides oncologists with strong evidence on 
the current treatment landscape among older adults with multimorbidity.  In addition, this study 
examined the factors associated with ICI use.  In the era of personalized medicines, patient-level 
factors play a critical role in treatment decisions.  This study sheds light on various factors that 
will help healthcare providers in reaching a successful treatment goal with their older patients. 
3.7. Conclusions 
The findings from this study suggest that despite evidence of improved survival benefits 
over chemotherapy, the adoption of ICI among older patients remain low. This study revealed 
disparities in ICI use even after five years since ICI approval and introduction in the US markets.  
However, multimorbidity was not a barrier to ICI use suggesting that future research is needed 




Percent with Immune Checkpoint Inhibitor (ICI) use by Selected Patient-level 
Characteristics among Older Adults (age >65 years) with Incident Late-stage 
Melanoma during 2012 and 2015 
Linked Surveillance, Epidemiology, and End Results and Medicare Claims Database 
 Variables 
ICI No ICI   
% % p-value Significance 
ALL 5.6 94.4   
Multimorbidity     
 Yes 5.5 94.5 0.62  
 No 6.0 94.0   
Year of diagnosis     
 2012 3.2 96.8 0.0008 *** 
 2013 5.8 94.2   
 2014 6.4 93.6   
 2015 6.8 93.2   
Age     
 66 to 69 years 6.8 93.2 0.0004 *** 
 70 to 74 years 7.6 92.4   
 75 to 79 years 5.0 95.0   
 ≥80 years 4.1 95.9   
Sex     
 Female 4.5 95.5 0.014 * 
 Male 6.2 93.8   
Race     
 Whites 5.5 94.5 0.29  
 Non-Whites 7.3 92.7   
Marital Status     
 Married 7.3 92.7 <0.0001 *** 
 Not married 3.9 96.1   
Dual Medicare/Medicaid eligibility   
 Yes 10.0 90.0 0.0104 * 
 No 5.4 94.6   
Regions     
 Northeast 7.9 92.1 0.0186 * 
 South 5.1 94.9   
 North Central 5.1 94.9   
 West 5.1 94.9   
Note: Based on 4,519 older adults with incident late-stage (Stage III/IV) melanoma 
continuously enrolled in Medicare Part A & B fee-for service programs 12 months prior 




Unadjusted Odds Ratio (OR), Adjusted Odds Ratios (AOR), and 95% Confidence Intervals (CI) from Logistic 
Regressions on Immune Checkpoint Inhibitor use 
Older Adults (age >65 years) with Incident Late-stage Melanoma during 2012 and 2015 
Linked Surveillance, Epidemiology, and End Results and Medicare Claims Database 
Variables 
Unadjusted analysis Fully Adjusted Analysis 
OR 95%CI Significance AOR 95%CI Significance 
Multimorbidity       
 Yes 0.82 [ 0.55 ,  1.22 ] 
 0.96 [ 0.67 , 1.37 ] 
 
 No (ref)   (ref)   
Year of diagnosis       
 2012 (ref)   (ref)   
 2013 2.03 [ 1.30 , 3.18 ] ** 1.82 [ 1.19 , 2.78 ] ** 
 2014 1.98 [ 1.27 , 3.09 ] ** 2.10 [ 1.39 , 3.18 ] *** 
 2015 0.78 [ 0.45 , 1.34 ]  2.38 [ 1.58 , 3.59 ] *** 
Age        
 65 to 69 years 1.82 [ 1.19 , 2.81 ] ** 1.63 [ 1.14 , 2.34 ] ** 
 70 to 74 years 2.19 [ 1.46 , 3.28 ] *** 1.79 [ 1.27 , 2.52 ] *** 
 75 to 79 years 1.42 [ 0.90 , 2.25 ]  1.18 [ 0.80 , 1.74 ]  
 >80 years (ref)   (ref)   
Sex        
 Females 0.67 [ 0.48 , 0.94 ] * 0.78 [ 0.58 , 1.04 ]  
 Males (ref)   (ref)   
Race        
 Whites (ref)   (ref)   
 Non-whites 1.53 [ 0.79 , 2.94 ]  1.17 [ 0.64 , 2.15]  
Marital Status       
 Married 1.99 [ 1.45 , 2.73 ] *** 1.94 [ 1.48 , 2.56 ] *** 
 Not married (ref)   (ref)   
Dual Medicare/Medicaid eligibility      
 Yes 1.99 [ 1.08 , 3.66 ] * 2.34 [ 1.35 , 4.03 ] ** 
 No (ref)   (ref)   
Region        
 North central 0.65 [ 0.36 , 1.17 ]  0.59 [ 0.36 , 0.95 ] * 
 West 0.72 [ 0.49 , 1.06 ]  0.57 [ 0.42 , 0.79 ] *** 
 South 0.64 [ 0.40 , 1.02 ]  0.56 [ 0.38 , 0.83 ] ** 
 Northeast (ref)   (ref)   
Note: Based on 4,519 older adults with incident late-stage (Stage III/IV) melanoma continuously enrolled in Medicare 
Parts A and B fee-for-service programs 12 months prior to incident cancer diagnosis.  *0.05< p ≤ 0.01; **0.01 < p 
≤0.001; *** p< 0.001 




4. IMMUNE CHECKPOINT INHIBITOR USE, MULTIMORBIDITY, AND 
HEALTHCARE EXPENDITURES AMONG OLDER ADULTS WITH LATE-STAGE 
MELANOMA 
4.1. Abstract 
Background: The objective of this study is to assess the impact of immune checkpoint inhibitors 
(ICI) and multimorbidity on healthcare expenditures among older patients with late-stage 
melanoma. 
Methods: A retrospective longitudinal cohort study using Surveillance, Epidemiology, and End 
Results linked with Medicare claims was conducted.  Generalized linear mixed models were 
used to analyze adjusted relationships of ICI, multimorbidity, and ICI-multimorbidity interaction 
on average healthcare expenditures. 
Results: Patients who received ICI and those who had multimorbidity had significantly higher 
average total healthcare expenditures compared to ICI nonusers and no multimorbidity.  In the 
fully adjusted model using ICI-multimorbidity interaction, no excess cost was added by 
multimorbidity. 
Conclusion: Use of ICIs, regardless of multimorbidity, is associated with increased healthcare 
expenditures. 
4.2. Introduction 
Cancer exerts a substantial burden on the morbidity and mortality of patients.122,123  In 
addition, cancer exerts a significant economic burden on not only the patients, but also on payers 
and society as well.50  Cancer is one of the top five most expensive chronic conditions.50  There 
is robust evidence showing that cancer substantially increases healthcare expenditures.124–127  For 
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example, it has been reported that adults with cancer have four times higher expenditures 
compared to those without cancer.51,127  Furthermore, the healthcare cost of cancer differs by the 
type and stage of cancer.  Healthcare costs were highest for cancers with poor survival rates such 
as brain cancers and lowest for cancers with high survival rates, such as melanoma.51  However, 
the cost increases substantially when the cancer metastasizes.50–52   For example, 55% of the 
annual direct costs for treating melanoma were related to treating late-stage melanoma.53 
While many factors can influence healthcare costs among cancer patients, expensive 
drugs approved for cancer, the administration of these drugs, and supportive care (monitoring, 
surveillance, and management of side-effects such as kidney infections, pneumonia through 
frequent medical office visits and sometimes hospitalizations) are some of the main factors.56  
For example, in metastatic melanoma patients initiated on an immune therapy agent ipilimumab, 
the average all-cause healthcare expenditures for a treatment episode was estimated to be 
$153,062.128 The immune checkpoint inhibitors (ICIs) were first approved for the treatment of 
late-stage melanoma nine years ago after their success in improving survival was established by 
randomized clinical trials (RCTs).92  However, the high cost of ICIs may hinder their widespread 
adoption in real-world clinical settings.  The average wholesale price in 2015 of a single dose for 
a 70 kg patient was $5,732 for nivolumab, $33,162 for ipilimumab, and $35,073 for the 
combination therapy.129  As these drugs need to be administered by healthcare professionals in 
outpatient settings, the total costs are even higher.130  This is compounded by the fact that an 
optimum dose for ICIs remains unknown which entails continuous use of ICI until regression of 
the tumor or appearance of adverse events.20,21,23  Oncologists estimated that treatment cost for 
the highest and most often administered dose, 26 courses of an ICI can be as high as $1,009,944 
with a 20% copay.57 
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Thus, a vast majority of patients cannot afford ICI treatment unless covered by health 
insurance.48,120,131,132  In the United States (US), insurance and type of insurance coverage are 
often associated with prognosis, treatment and survival of cancer patients. Specifically, using the 
National Cancer Database, Jain and coauthors (2020) reported that the stage of diagnosis and 
receipt of ICIs were associated with insurance status.133  A high proportion of individuals with 
late-stage melanoma were on Medicare and were as likely as those with commercial insurance to 
receive ICI.48,49  These findings suggest that Medicare may bear a disproportionate share of late-
stage melanoma expenditures.  Furthermore, older Medicare beneficiaries (age > 65 years) are of 
particular interest for several reasons; 96% are covered by Medicare; higher incidence of better 
cancer/late-stage melanoma is observed among these patients, and Medicare patients are facing 
an evolving payment landscape, such as Oncology Care Model (OCM), aimed towards 
improving cancer care continuum while reducing costs in older patients.10,134–136 
The newer payment models also include patients in high-risk groups, such as those with 
multimorbidity.136  This is because 68% of the Medicare population reported having 
multimorbidity and resulted in 80% of Medicare payments.29,137–139  Expert and systematic 
reviews have concluded that patients with multimorbidity have higher costs compared to those 
without multimorbidity.28,140  Patients with multimorbidity and cancer have higher expenditures 
compared to those without any multimorbidity.141,142  Furthermore, multimorbidity is highly 
prevalent in older adults with late-stage melanoma.143 If ICI are added to this mix, patients with 
multimorbidity and ICI may have even higher costs than those without multimorbidity and ICI.  
Therefore, the objectives of this study are (a) to estimate the impact of ICI use and (b) to assess 
the impact of the interaction of ICI and multimorbidity on healthcare expenditures among older 
patients with late-stage melanoma.  We hypothesize that ICI use will be associated with high 
46 
expenditures throughout the treatment period compared to those without ICI use, and those with 
multimorbidity and ICI will have even higher costs than those without multimorbidity and ICI. 
4.3. Methods 
Study design 
A retrospective observational longitudinal cohort design with a 12-month baseline (pre-
index) and a 12-month follow-up (post-index) period was used; incident diagnosis of late-stage 
(stage III/IV) melanoma diagnosis was defined as the index date.  Independent variables were 
assessed in the baseline period while treatments (chemotherapy, radiation, ICI) received were 
assessed in the follow-up period.  Healthcare expenditures were measured every 120 days (t1, t2, 
t3, t4, t5, and t6) during the 24-month observation period to ensure robust findings by reducing the 
“signal-to-noise” ratio144 (Figure 4.1). 
Data Sources 
Surveillance, Epidemiology, and End Results (SEER) cancer registry linked with fee-for-
service Medicare claims was used as the data source.  Information on clinical variables related to 
cancer (such as stage of cancer at diagnosis) was obtained from the SEER data. Information on 
healthcare encounters of beneficiaries when enrolled and using Medicare covered health services 
including Medicare payments, and provider settings was obtained from Medicare claims. 
Study Population 
The study population was comprised of older (>65 years) adults diagnosed with incident 
melanoma between 2012 and 2015, identified using ICD-O-3 site codes (C44.0 – C44.9) and 
ICI-O-3 histology codes (8720 – 8790).  Late-stage (stage III/IV) of melanoma was identified 
based on the TNM classification using American Joint Committee on Cancer 7th Edition.  After 
excluding patients with local or regional (stage I/II) melanoma, non-incident melanoma, ages 
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66 years and below, not continuously enrolled in fee-for-service Medicare part A and part B 
during the observation period, and diagnosed with late-stage cancer during autopsy, the final 
cohort consisted of 4,519 patients. 
Measures 
Dependent variable: Total and Type of Healthcare expenditures 
Total healthcare expenditures consisted of the sum of Medicare payments for inpatient, 
outpatient services (including carrier claims) for any care, home health care, and durable medical 
equipment.  We also analyzed type of healthcare expenditures by site of care (inpatient and 
outpatient, and home healthcare).  All healthcare expenditures were adjusted by the Consumer 
Price Index for medical services145 and expressed in 2016 USD. 
Independent variables 
The use of ICI (yes/no) was identified in the post-diagnosis period.  The three ICIs 
approved for late-stage melanoma treatment, ipilimumab, nivolumab, and pembrolizumab, were 
identified using healthcare common procedure coding system (HCPCS) codes (J9228, J9299, 
J9271).  Overlapping procedure codes for chemotherapy and ICI (96413, 96415) were excluded 
to ensure that chemotherapy was not misclassified as ICI. 
Multimorbidity (yes/no) was defined as the presence of two or more chronic conditions in 
in this study.  These conditions were obtained from a list of 18 chronic conditions developed by 
Multiple Chronic Conditions working group within the US Department of Health and Human 
Services Office of Assistant Secretary of Health.41  Pre-existing autoimmune diseases were 
added to the list based on the current challenges with ICI use in patients with these conditions.42  
All the chronic conditions were identified with International Classification of Diseases (ICD), 
9th Edition. 
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To examine the effects of ICI-multimorbidity interaction on cost, an ICI-multimorbidity 
interaction term was created, which was categorized into 4 groups: ICI and multimorbidity, ICI 
and no multimorbidity, No ICI and multimorbidity, and No ICI and no multimorbidity. 
Other independent variables included biological factors, social factors, community 
resources, economic status, and year of diagnosis.  Biological factors consisted of age (66-69 
years, 70-74 years, 75-79 years, and ≥80 years), sex (male/female), and race (white/non-white).  
Social factors included marital status (married/not married).  Oncologist visits (yes/no) and 
primary care physician visits (yes/no) were measured every 120 days.  Dual Medicare/Medicaid 
enrollment (yes/no) was used as a proxy for low economic status.  Years of incident melanoma 
diagnosis (2012-2015) was used to control for changes in practice patterns. 
Statistical Analyses 
Unadjusted subgroup differences in time-invariant characteristics between ICI users were 
tested with chi-square statistics.  The associations of ICI and multimorbidity to healthcare 
expenditures were tested within the framework of Generalized Linear Models (GLM) with 
gamma distribution and log-link.  This specification was chosen for GLM because of several 
reasons: (a) GLM does not require normal distribution of errors, (b) better aligns the variance 
function to the mean function, and (c) does not require smearing correction, which can be easily 
converted to original dollars.43  Modified Park test confirmed the choice of gamma distribution 
with log-link was selected.  As healthcare expenditures were measured every 120 days during the 
pre- and post-index periods, each individual had six observations.  However, these observations 
were not independent and therefore generalized linear mixed models (GLMMs) with gamma 
distribution and log-link was used to analyze adjusted relationships between ICI and non-ICI 
user groups and ICI-multimorbidity interaction.  The GLMMs included all independent variables 
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and time.  Both unadjusted and adjusted models used GLMMs.  Adjusted GLMMs included a 
time squared as one of the independent variables, to control for the non-linear relationship of 
healthcare expenditures over time.  All analyses were conducted on STATA (StataCorp 2015). 
4.4. Results 
The study population was comprised of predominantly of males (64.2%), Non-Hispanic 
Whites (96.1%) and those 70 years or older (70.4%).  Most older patients with late-stage 
melanoma had multimorbidity (85%) and 6% received ICI.  The mean time from index date to 
ICI initiation was 48 days.  The characteristics of the study population are presented in 
Appendix 7.3. 
Overall healthcare expenditures 
The average total, outpatient, home health, and inpatient healthcare expenditures in the 
pre-index period (t1, t2, and t3) were significantly (p < 0.001) lower than the expenditures in the 
post-index period (t4, t5, and t6) (Figure 4.2).  All healthcare expenditures in the 120-day post-
late-stage melanoma diagnosis period (t4) were significantly higher compared to other pre- and 
post-index time periods (t1, t2, t3, t5 and t6). 
Healthcare expenditures among ICI users and non-users 
The average total, outpatient, home healthcare, and inpatient healthcare expenditures 
were significantly higher among ICI users compared to non-ICI users.  Among ICI users, the 
average total and inpatient expenditures were significantly higher in t4 (representing 120 days 
after cancer diagnosis) compared to other time periods (t1, t2, t3, t5 and t6) while average 
outpatient and home healthcare expenditures did not differ significantly in t4 and t5 and t4 and t6 
time periods, respectively.  Among non-ICI users, average total, outpatient, home healthcare, and 
inpatient expenditures were significantly higher in t4 compared to other time periods. 
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Healthcare expenditures among those with and without multimorbidity 
The average total, outpatient, home healthcare, and inpatient healthcare expenditures 
were significantly higher among those with multimorbidity compared to those without 
multimorbidity.  Compared to t4, the average total, outpatient, home healthcare, and inpatient 
expenditures were significantly lower in other time periods (t1, t2, t3, t5 and t6) among those with 
multimorbidity.  The average home healthcare expenditure did not significantly differ in t4 and t6 
time periods among those without multimorbidity. 
Healthcare expenditures and ICI-multimorbidity interaction 
The average total, outpatient, home healthcare, and inpatient healthcare expenditures 
were significantly higher among ICI users and with multimorbidity group compared to ICI non-
users and without multimorbidity.  Average total expenditures by the ICI-multimorbidity groups 
are displayed in Figure 4.3.  Compared to t4, the average total, outpatient, home healthcare, and 
inpatient expenditures were significantly lower in other time periods (t1, t2, t3, t5 and t6) among 
ICI users and with multimorbidity. 
Adjusted associations of ICI and multimorbidity to total healthcare expenditures 
Table 4.1 presents the unadjusted and adjusted parameters of GLMM on average total 
healthcare expenditures.  The unadjusted and fully adjusted models showed similar results.  In 
the model that was adjusted for time and time-squared, those with ICI had significantly higher 
average expenditures than those without ICI (β=1.34, SE=0.52, p <0.001).  When adjusted for 
multimorbidity, ICI users and those with multimorbidity had higher average expenditures 
compared to ICI non-users or no multimorbidity.  In the fully adjusted model, the average total 
expenditure significantly increased with time (β=0.49, SE=0.04, p < 0.001).  Patients who 
received ICI (β=0.91, SE=0.07, p < 0.001) and those who had multimorbidity (β=0.72, SE=0.07, 
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p < 0.001) had significantly higher average total expenditures compared to those who did not 
receive ICI or did not have multimorbidity. 
Other variables with significant findings were age, dual eligibility, and visits to 
oncologists and primary care physicians.  Significantly higher average total expenditures were 
reported in patients aged 75 to 79 years (β=0.17, SE=0.07, p = 0.015) and 80 years and older 
(β=0.26, SE=0.06, p < 0.001) compared to those aged between 65 and 69 years, who were dual 
eligible (β=0.28, SE=0.11, p = 0.011) versus those who were not, who had visited oncologists 
(β=1.75, SE=0.05, p < 0.001) versus no oncologist visits, and who had visited primary care 
physician (β=1.38, SE=0.05, p < 0.001) versus no primary care physician visits. 
We also conducted GLMM on average total expenditures by ICI-multimorbidity 
interaction.  In the fully adjusted model, compared to no ICI/no multimorbidity, average total 
expenditures were significantly higher in all other groups, namely in patients who used ICI and 
had multimorbidity (β=17889.18, SE=1260.794, p < 0.001), who used ICI but did not have 
multimorbidity (β=16178.22, SE=2951.45, p < 0.001), and who did not use ICI but had 
multimorbidity (β=1510.35, SE=368.74, p < 0.001).  The contrast in average healthcare 
expenditures was examined by ICI use and multimorbidity by using ICI-no multimorbidity as the 
comparator group (Table 1).  In the fully adjusted model, the average total healthcare 
expenditure significantly increased with time (β=0.50, SE=0.04, p < 0.001). Patients who were 
non-ICI users and had multimorbidity (β=-0.73, SE=0.14, p < 0.001) and non-ICI users and with 
no multimorbidity (β=-1.51, SE=0.15, p < 0.001) had significantly lower costs compared to 
patients who were ICI users and had no multimorbidity.  However, there was no significant 
difference between patients who were ICI users and had multimorbidity and patients who were 
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ICI users and had no multimorbidity.  Other variables with significant findings were same as 
above. 
Adjusted relationships between ICI, multimorbidity, and type of healthcare expenditures 
The relationship between ICI and multimorbidity by type of expenditures (outpatient, 
home healthcare, and inpatient) was further explored.  The findings for average outpatient 
expenditures were similar to total expenditures (Appendix 7.4). 
While patient with multimorbidity had significantly higher average home healthcare and 
inpatient expenditures compared to those without multimorbidity, ICI use was not significantly 
associated with those expenditures (Appendix 7.5 and Appendix 7.6, respectively). Similarly, the 
unadjusted and adjusted models of the effect of ICI and multimorbidity interaction on average 
home healthcare and inpatient expenditures were similar.  In the fully adjusted model, the 
average home healthcare (β=0.19, SE=0.06, p = 0.002) and inpatient expenditure (β=1.56, 
SE=0.22, p < 0.001) significantly increased with time.  However, no significant difference was 
observed among the ICI and multimorbidity groups. 
4.5. Discussion 
This study confirms previous findings and also presents some new findings. First, this 
study reports that average healthcare expenditures significantly increased after a terminal cancer, 
i.e., late-stage melanoma, diagnosis, which is in line with published studies.  Cancer diagnosis 
exerts a huge financial burden on patients, payers, and healthcare systems, with four times higher 
costs in cancer cohort compared to the non-cancer cohort.3,7  Late-stage cancers tend to be more 
expensive than early-stage cancers.4,8,44,45  Although costs of early-stage versus late-stage 
melanoma were not compared, these findings still relay that late-stage melanoma diagnosis 
among older patients places enormous burden on the payers.  These findings have implications 
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for the new OCM that are being experimented by the CMS.  Under the OCM providers are 
expected to “provide higher quality, more highly coordinated oncology care at the same or lower 
cost to Medicare”.29 The OCM organizes care around six-month episodes.29  By providing 
information on total healthcare expenditures by time periods, our cost estimates can serve as 
benchmarks for episode-driven payments. 
Second, this study found that ICI use is associated with higher average healthcare 
expenditures among older Medicare beneficiaries with late-stage melanoma.  This is the first 
study to the best of our knowledge to assess the association of ICI use on healthcare expenditures 
among older adults with late-stage melanoma.  Despite having similar expenditures during the 
pre-index periods (t1, t2, and t3), use of ICI significantly increased post-index date (t4, t5, and t6) 
expenditures. As seen in our study, outpatient expenditures were the major drivers of healthcare 
expenditures, contributing to 83% of the total expenditures.  This study also found that ICI use 
was not associated with inpatient expenditures.  Taken together these findings suggest that 
healthcare costs of ICI users may be driven by supportive care.  Reasons for these findings are 
speculated as follows.  It is reported that administration costs associated with ICIs are higher 
compared to other therapies.15  Intravenous infusion of ICI requires constant monitoring by a 
healthcare professional, which may lead to higher healthcare utilization.46  Infusion reactions or 
immune-related adverse events may occur thereby increasing healthcare resource utilization.46  
Another possible reason could be the constant monitoring and testing of patients in the outpatient 
settings being treated with ICI.46  Prior to and after infusion, late-stage melanoma patients are 
usually tested for serum biomarkers, enzyme level, and blood count.46  The study findings 
confirm that cancer-related treatments have shifted from inpatient to outpatient settings.45,47 
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Third, older Medicare beneficiaries with multimorbidity had higher average total 
expenditures compared to those without multimorbidity.  Across a range of healthcare settings 
and population, disproportionately higher costs were accounted for in a small number of patients 
and multimorbidity was highly prevalent in those patients.48  A majority of older adults with late-
stage melanoma also had multimorbidity.38  Therefore, higher total expenditures among older 
adults with multimorbidity corroborates findings from other studies.6,36  Many alternatives to 
traditional healthcare practices and payment models are being considered to account for the 
complex need of patients with multimorbidity.35 Accountable Care Organizations and patient-
centered medical homes over traditional practice models and bundled payment of services, which 
is more patient-centric than disease-centric, are a few such efforts.35  Though there are numerous 
challenges to adopting such policies on a larger scale,35 future studies need to explore whether 
these emerging models are effective in providing value-based care at lower costs for cancer 
patients in general and late-stage cancer patients in particular. 
Fourth, the ICI-multimorbidity interaction revealed that multimorbidity did not play a 
significant role in the increase of expenditures.  Rather, the high expenditures were due to the use 
of ICI.  Although multimorbidity was associated with higher average expenditures in this study, 
the expenditures due to ICI use supersede those expenditures.  The possible reasons for the 
increased average expenditures with ICI use are discussed above.  These results further 
strengthen the need for newer payment models such as OCM, which focus on reducing cost of 
cancer care. 
4.6. Strengths and Limitations 
The findings of this study should be interpreted considering its limitations.  First, Part D 
costs were not included.  This is because patients with multimorbidity will have higher 
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prescription costs compared to those without multimorbidity.  This may show even higher costs 
for patients with multimorbidity, which would be unrelated to cancer care.  However, the current 
therapies for melanoma are covered under Part B.  Therefore, melanoma-related treatment costs 
were adequately captured in this study.  Second, information on severity of co-existing illnesses 
may have provided insights into cluster of conditions which may lead to higher healthcare 
expenditures.  Third, the findings of this study cannot be generalized to all Medicare 
beneficiaries as the study population was limited to only those residing in SEER regions.  Fourth, 
a 12-month follow-up period may not be adequately assessing the impact of various factors on 
healthcare expenditures.  However, the mean overall survival for late-stage melanoma is 
approximately a year.  Therefore, a 12-month follow-up period was chosen.  Despite these 
limitations, the study has several strengths.  This study adopted a longitudinal design and 
compared expenditures over time.  Additionally, no study to-date has focused on impact of ICI 
on healthcare expenditures among older adults with multimorbidity and late-stage melanoma.  
This study provides payers with strong evidence on the influences of various factors on 
healthcare expenditures. 
4.7. Conclusion 
The results of this study illustrate that the healthcare expenditures were higher after a 
late-stage melanoma diagnosis.  Use of ICIs and presence of multimorbidity were associated 
with higher expenditures.  Outpatient expenditures contributed largely to the increase in total 
expenditures.  However, the ICI-multimorbidity interaction revealed that ICI was the driving 
force behind the higher expenditures.  Future studies are needed to explore healthcare utilization 
among older patients with multimorbidity and late-stage melanoma and explore its effect on 
healthcare expenditures.  
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FIGURE 
Figure 4.1: Schematic of the study design.  Each individual was observed for 24 months with a 
12-month pre-index and 12-month post-index period.  Healthcare expenditures and selected 
independent variables were measured repeatedly every 120 days during the pre-index (t1, t2, and 






Figure 4.2: (a) Mean Total and Type of Healthcare Expenditures Over time; (b) Mean Total Healthcare Expenditures by ICI user 
status 
  
Based on 6 repeated observation of 4,519 older adults with incident late-stage (Stage III/IV) melanoma continuously enrolled in Medicare Parts A 
and B fee-for-service programs 12 months prior to incident cancer diagnosis. 
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FIGURE 
Figure 4.3: Mean total healthcare expenditures by ICI-Multimorbidity groups during pre-index 
and post-index periods 
 
Based on 6 repeated observation of 4,519 older adults with incident late-stage (Stage III/IV) melanoma 
continuously enrolled in Medicare Parts A and B fee-for-service programs 12 months prior to incident 
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TABLES 
Table 4.1: Parameter estimates of select variables of GLMM on average total healthcare 
expenditures 
Variables 
No Interaction With interaction 
Unadjusted analysis 
Beta SE Prob Beta SE Prob 
Time 0.83 0.04 <0.001 0.83 0.04 <0.001 
ICI use    N/A   
Yes 1.34 0.52 <0.001    
No (ref)      
Multimorbidity    N/A   
Yes 0.96 0.74 <0.001    
No (ref)      
ICI-Multimorbidity Interaction N/A      
Yes ICI and Yes Multimorbidity    0.19 0.10 0.051 
Yes ICI and No Multimorbidity    (ref)   
No ICI and Yes Multimorbidity    -0.97 0.09 <0.001 
No ICI and No Multimorbidity    -1.99 0.12 <0.001 
Time squared -0.15 0.01 <0.001 -0.15 0.01 <0.001 
   
 No Interaction With interaction 
 Fully adjusted analysis╪ 
 Beta SE Prob Beta SE Prob 
Time 0.49 0.04 <0.001 0.50 0.04 <0.001 
ICI use    N/A   
Yes 0.91 0.07 <0.001    
No (ref)      
Multimorbidity    N/A   
Yes 0.72 0.07 <0.001    
No (ref)      
ICI-Multimorbidity Interaction N/A      
Yes ICI and Yes Multimorbidity    0.02 0.16 0.90 
Yes ICI and No Multimorbidity    ((ref)   
No ICI and Yes Multimorbidity    -0.73 0.14 <0.001 
No ICI and No Multimorbidity    -1.51 0.15 <0.001 
Time squared -0.12 0.01 <0.001 -0.12 0.01 <0.001 
Note: Based on 6 repeated observation of 4,519 older adults with incident late-stage (Stage III/IV) 
melanoma continuously enrolled in Medicare Parts A and B fee-for-service programs 12 months prior to 
incident cancer diagnosis. 
╪Fully adjusted model also included year of diagnosis, age, sex, race, marital status, dual eligibility, 
oncologist visit, and primary care physician visits. 
Probability p<0.05 was considered significant 
Abbreviations: GLMM, Generalized linear mixed model; ICI, Immune checkpoint inhibitors; N/A, Not 
applicable; Prob, Probability; ref, Reference; SE, Standard error  
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CHAPTER 5 
5. SUMMARY AND CONCLUSION 
5.1. Summary of Findings and Discussion 
Pre-existing multimorbidity is prevalent among the elderly yet remains 
understudied among older patients with melanoma.  Patients with cancer often present with 
multiple chronic conditions, i.e. multimorbidity.65,66  Cancer is usually a manifestation of adverse 
lifestyles, such as smoking, obesity, and alcohol use, which are also the underlying causes of 
other chronic conditions.77  Therefore, as a person ages, they accumulate chronic conditions, 
thereby increasing the prevalence of multimorbidity in older ages, especially among the elderly 
(>65 years) patients with cancer.148  Despite being rampant in patients with cancer, 
multimorbidity is not included in cancer care.  This is because patients with multimorbidity are 
often excluded from randomized clinical trials (RCTs).72  Moreover, guidelines often adopt a 
“single-disease” approach, thereby posing a problem to oncologists on treating such patients.72  
Information on prevalence of pre-existing multimorbidity may shed light on the need to update 
guidelines to include multimorbidity in cancer care. 
While prevalence of multimorbidity in other cancers has been studied in detail, late-stage 
melanoma has not received wide attention.  This may be because late-stage melanoma is the 
deadliest form of skin cancer with a high mortality rate.24  However, this was also the first cancer 
for which immune checkpoint inhibitors (ICI) were approved for treatment.92  The clinical trials 
of ICIs reported a significant improvement in the mean overall survival of patients with late-
stage melanoma, increasing from six to eight months to up to five years.93,149,150  As survivors of 
late-stage melanoma may increase, knowledge on the prevalence of pre-existing multimorbidity 
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will assist healthcare providers personalize care for their older patients by creating guidelines 
with  chronic conditions in mind. 
Prevalence of pre-existing multimorbidity among older adults with late-stage 
melanoma is high.  This is the first study to explore the prevalence and factors associated with 
the presence and type of multimorbidity among older adults with late-stage melanoma in the US.  
This study found that pre-existing multimorbidity is highly prevalent among older adults with 
four out of five patients having two or more chronic conditions.  This study also notes that the 
most common comorbid conditions were cardiovascular, endocrine, and musculoskeletal 
diseases or a combination of the three in dyads and triads.  Cardiovascular, endocrine, and 
musculoskeletal diseases are highly prevalent in older adults.75,76  As these diseases and cancer 
share modifiable risk factors, with some studies stating a bidirectional relationship between 
them, our findings were not surprising.77–79  These findings point to the fact that healthcare 
providers managing patients with late-stage melanoma may need to routinely monitor for the 
presence of these conditions and coordinate their care with the primary care physicians. 
Various types of multimorbidity (any, physical health conditions [PHC], autoimmune 
diseases [AD], and mental health conditions [MHC] multimorbidity) and the risk factors 
associated with those multimorbidity were also explored.  This study confirms findings from 
previous studies that age is a risk-factor for any multimorbidity.29,33  The region of residence was 
also associated with multimorbidity; however, studies on regional variations are lacking for us to 
adequately explain these results.  The PHC multimorbidity shared risk-factors with any 
multimorbidity, perhaps because PHC contributed to the bulk of multimorbidity.  Pre-existing 
AD was one of the PHC focused on, because of its complicated relationship with ICIs and the 
surge of interest in this condition among the oncology community.  This study found that 
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although prevalence of pre-existing AD was not high, one in 10 older patients with late-stage 
melanoma will present with multimorbidity.  Moreover, sex, region, and social support as a risk 
factor for AD multimorbidity also mimicked the findings of a previous studies.36,82,83  
Oncologists should consider these risk factors when deciding if a drug acting via the immune 
system (such as ICI) is the best course of treatment for older patients.  About 30% of older adults 
with late-stage melanoma in this study were diagnosed with any MHC, consistent with 
literature.84,85  The risk factors associated with MHC were sex, social support, and dual 
Medicare/Medicaid eligibility, which was consistent with previous studies.86–90  These risk 
factors with MHC should be assessed in order to reduce further psychological distress and  
appropriate follow-up interventions. 
The treatment landscape of late-stage melanoma has changed since the approval of 
ICIs in 2011.  However, it is unknown if these changes have been implemented to real-
world clinical settings.  Despite the poor prognosis for survival, an overwhelming majority 
(82%) of older patients in this study did not receive any treatment for their late-stage melanoma, 
which was consistent with a previous study on chemotherapy for late-stage melanoma 
treatment.101  In addition, the rates of treatment with ICI in the study was very low (6%) and 
lower than that reported in recent studies.25,102,103  The reason speculated was due to the 
differences in the population studied.  The study also focused on older adults with 85% having 
pre-existing multimorbidity who may be at high risk for poor survival prognosis.  As evidence is 
still emerging on the side effect profile of ICIs compared to existing modalities,104 oncologists 
may be cautious in using ICI among older patients with late-stage melanoma. 
The factors associated with use of ICI among older patients with late-stage melanoma 
were determined to be lower age range, presence of social support in the form of a spouse, 
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having dual Medicare/Medicaid eligibility, residing in Northeast region, and recent years of 
diagnosis.  However, multimorbidity was not significantly associated with receipt of ICI 
suggesting that multimorbidity was not a barrier in the receipt of ICI.  Since guidelines on cancer 
care do not take multimorbidity into consideration, these results entail that those lack of 
guidelines may force oncologists to use newer therapies despite concerns regarding additional 
conditions. 
Healthcare expenditures in the United States are increasing.  However, healthcare 
expenditures associated with ICI use and multimorbidity among older-adults with late-
stage melanoma remain unknown.  This study reports that healthcare expenditures 
significantly increased after a terminal cancer, such as  late-stage melanoma, diagnosis, which is 
in line with published studies.50–52,127  Older patients who had multimorbidity and those who had 
used ICI had significantly higher healthcare expenditures compared to those who did not have 
multimorbidity and had not use ICIs.  Moreover, among ICI users, outpatient expenditures were 
the driving force behind total expenditures, accounting for 83% of the total expenditures.  This 
confirmed findings from previous studies that late-stage melanoma care have shifted from 
inpatient to outpatient settings.54,147  In addition, the administration costs associated with ICIs are 
higher compared to other therapies.130  The ICI-multimorbidity interaction revealed that 
irrespective of the multimorbidity status, ICI was the driving force behind the total healthcare 
expenditures.  This finding shows that expenditures associated with ICI use were higher than 
those accrued by multimorbidity.  Taken together, the use of ICI is significantly associated with 
higher total healthcare expenditures. 
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5.2. Implications and suggestions for future research 
The findings of this study suggest that oncologists will encounter four in five older late-
stage melanoma patients with multimorbidity.  With lack of late-stage melanoma treatment 
guidelines for older patients with multimorbidity, clinicians and other stakeholders should 
consider updating guidelines to better guide healthcare workers on treatment of such patients.  
The lack of clear evidence from clinical trials and guidelines may, therefore, leave oncologists 
guessing on treating older patients with newer therapies.  With an already poor prognosis 
associated with late-stage melanoma, ICIs may be used regardless of multimorbidity. 
Future studies exploring the outcomes, such as . overall survival, associated with ICI use 
for late-stage melanoma in older adults with multimorbidity may shed light on the effectiveness 
of ICI in this subpopulation.  Further, exploring the effect of various dyad and triad clusters of 
chronic conditions on survival after ICI use may provide useful information on conditions highly 
susceptible to adverse outcomes after ICI use.  For example, patients with pre-existing 
autoimmune diseases and cardiovascular diseases may not be good candidates for receiving ICI 
compared to patients with osteoporosis and depression.  This is because conditions like 
cardiovascular diseases have intersecting pathways with cancer, as explained above, and 
therefore, are adversely affected by ICI further exacerbating these conditions.  Health-related 
quality of life among ICI users and nonusers was not explored in this study.  Future studies can 
explore the humanistic burden of ICI use among older adults with or without multimorbidity. 
Healthcare expenditures were higher among ICI users, regardless of multimorbidity.  The 
newer payment models like Oncology Care Models are needed now more than ever to reduce 
healthcare expenditures.  This study provides policymakers, healthcare workers, and other 
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stakeholders with a starting point for curbing the high expenditures among older patients with 
late-stage melanoma. 
Future studies can further explore the healthcare utilization among these patients and the 
difference in healthcare expenditures between ICI users and non-users.  Moreover, future studies 
can also include Part D expenditures.  Prescription drug expenditures may be higher among 
patients with multimorbidity compared to those without multimorbidity.  Therefore, the 
healthcare expenditures of older patients with multimorbidity may be even higher.  These studies 
will strengthen the need for preventative measures to avoid multimorbidity among the elderly. 
5.3. Strengths and Limitations 
The present study has several limitations.  First, SEER does not contain information on 
individual behavior such as smoking status, alcohol consumption, or functional status, all of 
which can further affect the risk of having multimorbidity.  Second, individual-level 
socioeconomic factors, such as education and income were not available.  Third, information on 
severity of co-existing illnesses may have provided insights into whether the intake is low 
because of competing demands that may confer high mortality risk and may have precluded the 
use of ICI.  Fourth, the reasons for not receiving any treatment in older patients was unknown.  
Though disparities in ICI use were observed, the reason for these disparities, whether due to 
patient preferences or shared decision-making of providers and patients, could not be evaluated.  
Such information could direct healthcare providers on measures that can be taken to enhance the 
adoption of ICIs.  Fifth, the database did not have detailed information on tumor characteristics 
or genetic markers such as BRAF status.  Information on these could provide further insights into 
use of ICIs.  Sixth, Part D medications were unavailable to us and therefore, prescription 
expenditure was not included.  However, the current therapies for melanoma are covered under 
66 
Part B.  Therefore, melanoma-related treatment costs were adequately captured in this study.  
Seventh, a 12-month follow-up period may not be adequately assessing the impact of various 
factors on healthcare expenditures.  However, the mean overall survival for late-stage melanoma 
is approximately a year.  Therefore, a 12-month follow-up period was chosen. 
Despite these limitations, this study has several strengths.  Although few studies on 
comorbid conditions in individuals with melanoma exist, they did not focus on late-stage 
melanoma, perhaps because the prognosis was poor with low chances of survival.91  Therefore, 
prognostic burden of multimorbidity in such individuals was deemed less important.91  However, 
newer therapies such as ICIs will improve survivorship of patients with late-stage melanoma.  
Therefore, information on the prevalence and type of multimorbidity in such individuals can help 
both physicians and patients in choice of cancer treatment, survivorship plans, and quality of life 
care.  An exhaustive list of PHC and MHC, including pre-existing AD was included.  Moreover, 
no study to-date has focused on treatment of older adults with multimorbidity and late-stage 
melanoma.  With a high prevalence, oncologists are bound to encounter such patients on a daily 
basis. This study provides oncologists with strong evidence on the current treatment landscape 
among older adults with multimorbidity.  In addition, this study examined the factors associated 
with ICI use.  In the era of personalized medicines, patient-level factors play a critical role in 
treatment decisions.  This study sheds light on various factors that will help healthcare providers 
in reaching a successful treatment goal with their older patients.  The study on healthcare 
expenditure adopted a longitudinal design and compared expenditures over time.  The 
longitudinal design allowed us to minutely look at the various time points pre- and post- cancer 
diagnosis and evaluated the reasons for changing expenditures in during each time point.  This 
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study provides payers with strong evidence on the influences of various factors on healthcare 
expenditures. 
5.4. Conclusion 
This dissertation concludes that prevalence of multimorbidity among older adults with 
late-stage melanoma is high.  However, multimorbidity is not a barrier to access to ICIs.  
Multimorbidity is associated with higher expenditures compared to no multimorbidity.  
However, when the patients were treated with ICI, the healthcare expenditures increased 
significantly and the presence or absence of multimorbidity did not change the results.  Clinical 
trials have shown that the ICIs have drastically improved survival of patients with late-stage 
melanoma; however, they come with a hefty price tag.  Future studies are needed to examine 
overall survival among older patients with multimorbidity treated with ICIs to assess the risk-
benefit of these newer therapies for late-stage melanoma.  
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Appendix 7.1: List of autoimmune diseases 
S.No. Autoimmune disease 
1 Achalasia 
2 Addison's disease 
3 Adult Still's disease 
4 Agammaglobulinemia 
5 Alopecia areata 
6 Amyloidosis 
7 Ankylosing spondylitis 
8 Anti-GBM/Anti-TBM nephritis 
9 Antiphospholipid syndrome 
10 Autoimmune angioedema 
11 Autoimmune dysautonomia 
12 Autoimmune encephalomyelitis 
13 Autoimmune heptatitis 
14 Autoimmune inner ear disease (AIED) 
15 Autoimmune myocarditis 
16 Autoimmune oophoritis 
17 Autoimmune orchitis 
18 Autoimmune pancreatitis 
19 Autoimmune retinopathy 
20 Autoimmune urticaria 
21 Axonal & neuronal neuropathy (AMAN) 
22 Balo disease 
23 Benign mucosal pemphigoid 
24 Castleman disease 
25 Celiac disease 
27 Chagas disease 
27 Chronic inflammatory demyelinating polyneuropathy (CIDP) 
28 Chronic recurrent multifocal osteomyelitis (CRMO) 
29 Cicatricial pemphigoid 
30 Cogan's syndrome 
31 Cold agglutinin disease 
32 Congenital heart block 
33 Coxsackie myocarditis 
34 CREST syndrome 
35 Crohn's disease 
36 Dermatitis herpetiformis 
37 Dermatomyositis 
38 Devic's disease (neuromyelitis optica) 
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S.No. Autoimmune disease 
39 Discoid lupus 
40 Dressler's syndrome 
41 Endometriosis 
42 Eosinophilic esophagitis (EoE) 
43 Eosinophilic fascitis 
44 Erythema nodosum 
45 Evan syndrome 
46 Fibromyalgia 
47 Fibrosing alveolitis 
48 Giant cell myocarditis 
49 Glomerulonephritis 
50 Goodpasture's syndrome 
51 Grave's disease 
52 Guillain-Barre syndrome 
53 Hashimoto's thyroiditis 
54 Hemolytic anemia 
55 Herpes gestationis or pemphigoid gestationis (PG) 
56 Hiradenitis Suppurativa (HS) (Acne inversa) 
57 Hypogammalglobulinemia 
58 IgA Nephropathy 
59 IgG4-related sclerosing disease 
60 Immune thrombocytopic purpura (ITP) 
61 Inclusion body myositis (IBM) 
62 Interstitial cystitis 
63 Kawasaki disease 
64 Lambert-eaton syndrome 
65 Leukocytoclastic vasculitis 
66 Lichen planus 
67 Ligenous conjuctivitis 
68 Linear IgA disease (LAD) 
69 Lupus 
70 Lyme disease chronic 
71 Meniere's disease 
72 Mixed connective tissure disease 
73 Mooren's ulcer 
74 Mucha-Habermann disease 
75 Multifocal motor neuropathy  
76 Multiple sclerosis 
77 Myasthenia gravis 
78 Myositis 
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S.No. Autoimmune disease 
79 Narcolepsy 
80 Neuromyelitis optica 
81 Neutropenia 
82 Ocular cicatricial pemphigoid 
83 Optic neuritis 
84 Palindromic rheumatism 
85 Paraneoplastic cerebellar degeneration 
86 Paroxysmal noctural hemoglobinuria 
87 Parry Romberg syndrome 
88 Pars planitis (peripheral uveitis) 
89 Parsonage-Turner syndrome 
90 Pemphigus 
91 Peripheral neuropathy 
92 Perivenous encephalomyelitis 
93 Pernicious anemia 
94 
Polyneuropathy, organomegaly, endocrinopathy, monoclonal 
gammopathy, skin changes (POEMS syndrome) 
95 Polyglandular syndromes type I, II, III 
96 Polymyositis 
97 Postmyocardial infarction syndrome 
98 Postpericardiotomy syndrome 
99 Primary biliary cirrhosis 
100 Primary sclerosing cholangitis 
101 Progesterone dermatitis 
102 Psoriasis 
103 Psoriatic arthritis 
104 Pure red cell aplasia 
105 Pyoderma gangrenosum 
106 Raynaud's phenomenon 
107 Reactive arthritis 
108 Reflex sympathetic dystrophy 
109 Relapsing polychondritis 
110 Restless legs syndrome 
111 Retroperitoneal fibrosis 
112 Rheumatic fever 
113 Rheumatic arthritis 
114 Sarcoidosis 
115 Schmidt syndrome 
116 Scleritis 
117 Sjogren's syndrome 
118 Stiff person syndrome 
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S.No. Autoimmune disease 
119 Subacute bacterial endocarditis 
120 Susac's syndrome 
121 Sympathetic ophthalmia 
122 Takayasu's arteritis 
123 Thrombocytopenic purpura 
124 Tolosa-Hunt syndrome 
125 Transverse myelitis 
126 Ulcerative colitis 
127 Undifferentiated connective tissue disease 
128 Uveitis, Panuveitis 
129 Vasculitis 
130 Vitiligo 
131 Vogt-Koyanagi-Harada disease 
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Appendix 7.2: Codes for identification of chemotherapy and radiation for the treatment of late-stage melanoma 
Chemotherapy HCPCS Codes CPT Codes 
Amifostine  'J0207'  '96374' 
Bacillus Calmette-Guérin  '90585', '90586', 'J9031'  '90471', '90472' 
Bleomycin  'J9040'  '96401', '96409' 
Carboplatin  'J9045'  '96409', '96413'⁑, '96415'⁑ 
Cisplatin  'J9060'  '96409', '96413',⁑ '96415'⁑ 
Carmustine  'J9050'  '96413', '96415'⁑ 
Dacarbazine  'J9130'  '96409', ' 96413'⁑ 
Docetaxel  'J9171 '  '96413⁑' 
Granulocyte-macrophage colony-stimulating 
factor 
 'J2820'  '96365', '96366', '96372' 
IL-2- aldesleukin  'J9015'  '96409' 
Interferon alfa-2b  'C9399',* 'J9999'*  '96372', '96401' 
Lomustine  'J8999'*, 'S0178'  - 
Megestrol acetate  'J8999'*, 'S0179'  - 
Melphalan  'J9245'  '96409', '96413'⁑ 
Nab-paclitaxel  'J9264'  - 
Paclitaxel  'J9265'  '96413'⁑, '96415'⁑ 
Temozolomide  'J8700'  - 
Vincristine  'J9370'  '96409' 
Vinblastine  'J9360'  '96409' 
Radiation HCPCS Codes CPT Codes 
Intensity Modulated Radiation Therapy  -  '77301', '77338' 
Stereotactic Body Radiation Therapy  'G0339', 'G0340'  '77373', '77435' 
2D and 3D Conformal 'G6003', 'G6004', 'G6005', 'G6006', 'G6007', 
'G6008', 'G6009', 'G6010', 'G6011', 'G6012', 'G6013', 
'G6014' 
 '77280', '77285', '77290',  
'77295', '77402', '77407', '77412' 
Stereotactic Radiosurgery  'G0339', 'G0340'  '77371', '77372', '77432' 
Brachytherapy 
 
 '67218', '77316', '77317', 
'77318', '77778' 




Percent with Immune Checkpoint Inhibitor (ICI) use by Selected Patient-level Characteristics 
among Older Adults (age >65 years) with Incident Late-stage Melanoma during 2012 and 2015 
Linked Surveillance, Epidemiology, and End Results and Medicare Claims Database 
 
Characteristics 
ALL ICI No ICI 
p-value Significance  % % % 
ALL 100 5.6 94.4   
Year of diagnosis      
 2012 24.2 3.2 96.8 0.0008 *** 
 2013 24.1 5.8 94.2   
 2014 25.8 6.4 93.6   
 2015 25.9 6.8 93.2   
Multimorbidity      
 Yes 84.8 5.5 94.5 0.62  
 No 15.2 6.0 94.0   
Age (in years)      
 65 to 69 20.2 6.8 93.2 0.0004 *** 
 70 to 74 22.2 7.6 92.4   
 75 to 79 20 5.0 95.0   
 80 and older 37.5 4.1 95.9   
Sex       
 Females 35.8 4.5 95.5 0.014 * 
 Males 64.2 6.2 93.8   
Race       
 Whites 96.1 5.5 94.5 0.29  
 Non-Whites 3.9 7.3 92.7   
Marital status      
 Unmarried 50.9 7.3 92.7 <0.0001 *** 
 Married 49.1 3.9 96.1   
Dual Medicare/Medicaid eligibility    
 Yes 3.8 10.0 90.0 0.0104 * 
 No 96.2 5.4 94.6   
Oncologist visits      
 Yes 20.0 12.5 87.5 <0.0001 *** 
 No 80.0 3.8 96.2   
Primary care physicians      
 Yes 62.0 6.2 93.8 <0.0001 *** 
 No 38.0 4.6 95.4   
Note: Based on 4,519 older adults with incident late-stage (Stage III/IV) melanoma continuously enrolled in 
Medicare Part A & B fee-for service programs 12 months prior to incident cancer diagnosis.
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Appendix 7.4: Parameter estimates of select variables of GLMM on average outpatient expenditures 
Variables 
No Interaction With interaction 
Unadjusted analysis 
Beta SE Prob Beta SE Prob 
Time 0.40 0.04 <0.001 0.41 0.04 <0.001 
ICI use    N/A   
Yes 1.66 0.05 <0.001    
No (ref)      
Multimorbidity    N/A   
Yes 0.93 0.07 <0.001    
No (ref)      
ICI-Multimorbidity Interaction N/A      
Yes ICI and Yes Multimorbidity    0.25 0.09 0.005 
Yes ICI and No Multimorbidity    (ref)   
No ICI and Yes Multimorbidity    -1.26 0.08 <0.001 
No ICI and No Multimorbidity    -2.24 0.11 <0.001 
Time squared -0.07 0.01 <0.001 -0.07 0.01 <0.001 
   
 No Interaction With interaction 
 Fully adjusted analysis╪ 
 Beta SE Prob Beta SE Prob 
Time 0.17 0.03 <0.001 0.18 0.03 <0.001 
ICI use    N/A   
Yes 1.18 0.07 <0.001    
No (ref)      
Multimorbidity    N/A   
Yes 0.77 0.07 <0.001    
No (ref)      
ICI-Multimorbidity Interaction N/A      
Yes ICI and Yes Multimorbidity    0.05 0.17 0.77 
Yes ICI and No Multimorbidity    (ref)   
No ICI and Yes Multimorbidity    -0.97 0.16 <0.001 
No ICI and No Multimorbidity    -1.79 0.17 <0.001 
Time squared -0.06 0.01 <0.001 -0.06 0.01 <0.001 
Note: Based on 6 repeated observations of 4,519 older adults with incident late-stage (Stage III/IV) 
melanoma continuously enrolled in Medicare Parts A and B fee-for-service programs 12 months prior to 
incident cancer diagnosis. 
╪Fully adjusted model also included year of diagnosis, age, sex, race, marital status, dual eligibility, 
oncologist visit, and primary care physician visits. 
Probability p<0.05 was considered significant 
Abbreviations: GLMM, Generalized linear mixed model; ICI, Immune checkpoint inhibitors; N/A, Not 
applicable; Prob, Probability; ref, Reference; SE, Standard error 
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Appendix 7.5: Parameter estimates of select variables of GLMM on average home healthcare expenditures 
Variables 
No Interaction With interaction 
Unadjusted analysis 
Beta SE Prob Beta SE Prob 
Time 0.33 0.06 <0.001 0.33 0.06 <0.001 
ICI use    N/A   
Yes 0.23 0.13 0.820    
No (ref)      
Multimorbidity    N/A   
Yes 1.64 0.16 <0.001    
No (ref)      
ICI-Multimorbidity Interaction N/A      
Yes ICI and Yes Multimorbidity    0.81 0.31 0.009 
Yes ICI and No Multimorbidity    (ref)   
No ICI and Yes Multimorbidity    0.79 0.30 0.008 
No ICI and No Multimorbidity    -0.93 0.34 0.006 
Time squared -0.05 0.01 <0.001 -0.06 0.01 <0.001 
  
 Fully adjusted analysis╪ 
 Beta SE Prob Beta SE Prob 
Time 0.19 0.06 0.002 0.20 0.07 0.002 
ICI use    N/A   
Yes 0.12 0.25 0.622    
No (ref)      
Multimorbidity    N/A   
Yes 1.21 0.19 <0.001    
No (ref)      
ICI-Multimorbidity Interaction N/A      
Yes ICI and Yes Multimorbidity    0.06 0.62 0.928 
Yes ICI and No Multimorbidity    (ref)   
No ICI and Yes Multimorbidity    0.24 0.61 0.696 
No ICI and No Multimorbidity    -1.07 0.63 0.092 
Time squared -0.05 0.01 <0.001 -0.05 0.01 <0.001 
Note: Based on 6 repeated observations of 4,519 older adults with incident late-stage (Stage III/IV) 
melanoma continuously enrolled in Medicare Parts A and B fee-for-service programs 12 months prior to 
incident cancer diagnosis. 
╪Fully adjusted model also included year of diagnosis, age, sex, race, marital status, dual eligibility, 
oncologist visit, and primary care physician visits. 
Probability p<0.05 was considered significant 
Abbreviations: GLMM, Generalized linear mixed model; ICI, Immune checkpoint inhibitors; N/A, Not 
applicable; Prob, Probability; ref, Reference; SE, Standard error  
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Appendix 7.6: Parameter estimates of select variables of GLMM on average inpatient expenditures 
Variables 
No Interaction With interaction 
Unadjusted analysis 
Beta SE Prob Beta SE Prob 
Time 1.94 0.17 <0.001 1.93 0.17 <0.001 
ICI use    N/A   
Yes 0.68 0.17 <0.001    
No (ref)      
Multimorbidity    N/A   
Yes 1.05 0.15 <0.001    
No (ref)      
ICI-Multimorbidity Interaction N/A      
Yes ICI and Yes Multimorbidity    0.20 0.34 0.551 
Yes ICI and No Multimorbidity    (ref)   
No ICI and Yes Multimorbidity    -0.27 0.29 0.342 
No ICI and No Multimorbidity    -1.40 0.32 <0.001 
Time squared -0.34 0.03 <0.001 -0.33 0.03 <0.001 
 No Interaction With interaction 
 Fully adjusted analysis╪ 
 Beta SE Prob Beta SE Prob 
Time 1.56 0.22 <0.001 1.56 0.22 <0.001 
ICI use    N/A   
Yes -0.07 0.16 0.676    
No (ref)      
Multimorbidity    N/A   
Yes 0.63 0.25 0.011    
No (ref)      
ICI-Multimorbidity Interaction N/A      
Yes ICI and Yes Multimorbidity    0.02 0.31 0.961 
Yes ICI and No Multimorbidity    (ref)   
No ICI and Yes Multimorbidity    0.21 0.29 0.463 
No ICI and No Multimorbidity    -0.46 0.35 0.179 
Time squared -0.30 0.04 <0.001 -0.30 0.04 <0.001 
Note: Based on 6 repeated observation of 4,519 older adults with incident late-stage (Stage III/IV) 
melanoma continuously enrolled in Medicare Parts A and B fee-for-service programs 12 months prior to 
incident cancer diagnosis. 
╪Fully adjusted model also included year of diagnosis, age, sex, race, marital status, dual eligibility, 
oncologist visit, and primary care physician visits. 
Probability p<0.05 was considered significant 
Abbreviations: GLMM, Generalized linear mixed model; ICI, Immune checkpoint inhibitors; N/A, Not 
applicable; Prob, Probability; ref, Reference; SE, Standard error 
